QUARTERLY REPORT
Q3 FY2021 — Quarterly report (Form 10-Q)
Q3 FY2021PDF · 53 pages442 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark one)
x True QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 2021
OR
o False TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
THE PROCTER & GAMBLE COMPANY
(Exact name of registrant as specified in its charter)
Ohio OH 1-434 31-0411980
(State of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number)
One Procter & Gamble Plaza Cincinnati OH
One Procter & Gamble Plaza, Cincinnati, Ohio 45202
(Address of principal executive offices) (Zip Code)
(513) 983-1100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, without Par Value PG NYSE
2.000% Notes due 2021 PG21 NYSE
2.000% Notes due 2022 PG22B NYSE
1.125% Notes due 2023 PG23A NYSE
0.500% Notes due 2024 PG24A NYSE
0.625% Notes due 2024 PG24B NYSE
1.375% Notes due 2025 PG25 NYSE
4.875% EUR notes due May 2027 PG27A NYSE
1.200% Notes due 2028 PG28 NYSE
1.250% Notes due 2029 PG29B NYSE
1.800% Notes due 2029 PG29A NYSE
6.250% GBP notes due January 2030 PG30 NYSE
5.250% GBP notes due January 2033 PG33 NYSE
1.875% Notes due 2038 PG38 NYSE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes þ No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for
such shorter period that the registrant was required to submit such files).
Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer,"
"accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer þ Accelerated filer ¨
Non-accelerated filer ¨ Smaller reporting company ¨ False
Emerging growth company ¨ False
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of
the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes o No þ False
There were 2,448,232,786 shares of Common Stock outstanding as of March 31, 2021.
-- 1 of 53 --
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
Three Months Ended March 31 Nine Months Ended March 31
Amounts in millions except per share amounts 2021 2020 2021 2020
NET SALES $ 18,109 $ 17,214 $ 57,172 $ 53,252
Cost of products sold 8,922 8,716 27,317 26,308
Selling, general and administrative expense 5,402 5,045 15,409 14,719
OPERATING INCOME 3,785 3,453 14,446 12,225
Interest expense (106) (100) (385) (308)
Interest income 11 39 30 133
Other non-operating income/(expense), net 187 106 (40) 323
EARNINGS BEFORE INCOME TAXES 3,877 3,498 14,051 12,373
Income taxes 628 541 2,607 2,056
NET EARNINGS 3,249 2,957 11,444 10,317
Less: Net earnings/(loss) attributable to noncontrolling interests (20) 40 44 90
NET EARNINGS ATTRIBUTABLE TO PROCTER & GAMBLE $ 3,269 $ 2,917 $ 11,400 $ 10,227
NET EARNINGS PER SHARE
Basic $ 1.30 $ 1.15 $ 4.53 $ 4.03
Diluted $ 1.26 $ 1.12 $ 4.37 $ 3.89
DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING 2,590.3 2,613.3 2,610.4 2,630.3
Basic net earnings per share and Diluted net earnings per share are calculated on Net earnings attributable to Procter & Gamble.
(1)
(1)
See accompanying Notes to Consolidated Financial Statements.
-- 2 of 53 --
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Three Months Ended March 31 Nine Months Ended March 31
Amounts in millions 2021 2020 2021 2020
NET EARNINGS $ 3,249 $ 2,957 $ 11,444 $ 10,317
OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX
Foreign currency translation (598) (1,164) 639 (1,312)
Unrealized gains/(losses) on investment securities 5 (6) 19 (12)
Unrealized gains on defined benefit retirement plans 194 185 24 327
TOTAL OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX (399) (985) 682 (997)
TOTAL COMPREHENSIVE INCOME 2,850 1,972 12,126 9,320
Less: Total comprehensive income/(loss) attributable to noncontrolling interests (21) 29 50 73
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO PROCTER & GAMBLE $ 2,871 $ 1,943 $ 12,076 $ 9,247
See accompanying Notes to Consolidated Financial Statements.
-- 3 of 53 --
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
Amounts in millions March 31, 2021 June 30, 2020
Assets
CURRENT ASSETS
Cash and cash equivalents $ 10,007 $ 16,181
Accounts receivable 4,861 4,178
INVENTORIES
Materials and supplies 1,548 1,414
Work in process 710 674
Finished goods 3,744 3,410
Total inventories 6,002 5,498
Prepaid expenses and other current assets 1,738 2,130
TOTAL CURRENT ASSETS 22,608 27,987
PROPERTY, PLANT AND EQUIPMENT, NET 21,103 20,692
GOODWILL 40,612 39,901
TRADEMARKS AND OTHER INTANGIBLE ASSETS, NET 23,658 23,792
OTHER NONCURRENT ASSETS 8,797 8,328
TOTAL ASSETS $ 116,778 $ 120,700
Liabilities and Shareholders' Equity
CURRENT LIABILITIES
Accounts payable $ 12,134 $ 12,071
Accrued and other liabilities 11,109 9,722
Debt due within one year 8,773 11,183
TOTAL CURRENT LIABILITIES 32,016 32,976
LONG-TERM DEBT 21,053 23,537
DEFERRED INCOME TAXES 5,977 6,199
OTHER NONCURRENT LIABILITIES 10,813 11,110
TOTAL LIABILITIES 69,859 73,822
SHAREHOLDERS’ EQUITY
Preferred stock 873 897
Common stock – shares issued – March 2021 4,009.2
June 2020 4,009.2 4,009 4,009
Additional paid-in capital 64,682 64,194
Reserve for ESOP debt retirement (1,006) (1,080)
Accumulated other comprehensive loss (15,489) (16,165)
Treasury stock (112,147) (105,573)
Retained earnings 105,674 100,239
Noncontrolling interest 323 357
TOTAL SHAREHOLDERS’ EQUITY 46,919 46,878
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 116,778 $ 120,700
See accompanying Notes to Consolidated Financial Statements.
-- 4 of 53 --
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
Three Months Ended March 31, 2021
Dollars in millions;
shares in thousands
Common Stock Preferred
Stock
Add-itional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumu-lated
Other
Comp-rehensive
Income/(Loss) Treasury Stock Retained
Earnings Non-controlling
Interest
Total Share-
holders'
Equity Shares Amount
BALANCE
DECEMBER 31, 2020 2,462,476 $4,009 $885 $64,672 ($1,072) ($15,091) ($109,583) $104,361 $359 $48,540
Net earnings 3,269 (20) 3,249
Other comprehensive
income/(loss) (398) (1) (399)
Dividends and dividend
equivalents ($0.7907 per share):
Common (1,952) (1,952)
Preferred, net of tax benefits (65) (65)
Treasury stock purchases (23,085) (3,001) (3,001)
Employee stock plans 7,605 8 427 435
Preferred stock conversions 1,237 (12) 2 10 —
ESOP debt impacts 66 61 127
Noncontrolling interest, net (15) (15)
BALANCE
MARCH 31, 2021 2,448,233 $4,009 $873 $64,682 ($1,006) ($15,489) ($112,147) $105,674 $323 $46,919
Nine Months Ended March 31, 2021
Dollars in millions;
shares in thousands
Common Stock Preferred
Stock
Add-itional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumu-lated
Other
Comp-rehensive
Income/(Loss) Treasury Stock
Retained
Earnings
Non-controlling
Interest
Total Share-
holders'
Equity Shares Amount
BALANCE
JUNE 30, 2020 2,479,746 $4,009 $897 $64,194 ($1,080) ($16,165) ($105,573) $100,239 $357 $46,878
Net earnings 11,400 44 11,444
Other comprehensive
income/(loss) 676 6 682
Dividends and dividend
equivalents
($2.3721 per share)
Common (5,887) (5,887)
Preferred, net of tax benefits (197) (197)
Treasury stock purchases (59,212) (8,009) (8,009)
Employee stock plans 24,945 484 1,415 1,899
Preferred stock conversions 2,754 (24) 4 20 —
ESOP debt impacts 74 119 193
Noncontrolling interest, net (84) (84)
BALANCE
MARCH 31, 2021 2,448,233 $4,009 $873 $64,682 ($1,006) ($15,489) ($112,147) $105,674 $323 $46,919
See accompanying Notes to Consolidated Financial Statements.
-- 5 of 53 --
Three Months Ended March 31, 2020
Dollars in millions;
shares in thousands
Common Stock Preferred
Stock
Add-itional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumu-lated
Other
Comp-rehensive
Income/(Loss) Treasury Stock
Retained
Earnings
Non-controlling
Interest
Total Share-
holders'
Equity Shares Amount
BALANCE
DECEMBER 31, 2019 2,469,453 $4,009 $911 $64,019 ($1,112) ($14,942) ($105,761) $98,414 $370 $45,908
Net earnings 2,917 40 2,957
Other comprehensive
income/(loss) (974) (11) (985)
Dividends and dividend
equivalents
($0.7459 per share):
Common (1,850) (1,850)
Preferred, net of tax benefits (64) (64)
Treasury stock purchases (7,313) (901) (901)
Employee stock plans 12,234 (44) 829 785
Preferred stock conversions 1,269 (11) 1 10 —
ESOP debt impacts 32 57 89
Noncontrolling interest, net 2 2
BALANCE
MARCH 31, 2020 2,475,643 $4,009 $900 $63,976 ($1,080) ($15,916) ($105,823) $99,474 $401 $45,941
Nine Months Ended March 31, 2020
Dollars in millions;
shares in thousands
Common Stock Preferred
Stock
Add-itional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumu-lated
Other
Comp-rehensive
Income/(Loss) Treasury Stock
Retained
Earnings
Non-controlling
Interest
Total Share-
holders'
Equity Shares Amount
BALANCE
JUNE 30, 2019 2,504,751 $4,009 $928 $63,827 ($1,146) ($14,936) ($100,406) $94,918 $385 $47,579
Net earnings 10,227 90 10,317
Other comprehensive
income/(loss) (980) (17) (997)
Dividends and dividend
equivalents (2.2377 per share):
Common (5,587) (5,587)
Preferred, net of tax benefits (193) (193)
Treasury stock purchases (61,346) (7,405) (7,405)
Employee stock plans 28,965 145 1,964 2,109
Preferred stock conversions 3,273 (28) 4 24 —
ESOP debt impacts 66 109 175
Noncontrolling interest, net (57) (57)
BALANCE
MARCH 31, 2020 2,475,643 $4,009 $900 $63,976 ($1,080) ($15,916) ($105,823) $99,474 $401 $45,941
See accompanying Notes to Consolidated Financial Statements.
-- 6 of 53 --
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended March 31
Amounts in millions 2021 2020
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD $ 16,181 $ 4,239
OPERATING ACTIVITIES
Net earnings 11,444 10,317
Depreciation and amortization 2,025 2,199
Loss on early extinguishment of debt 512 —
Share-based compensation expense 398 325
Deferred income taxes (167) (588)
Loss/(gain) on sale of assets (15) 11
Changes in:
Accounts receivable (604) 135
Inventories (399) (533)
Accounts payable, accrued and other liabilities 1,049 738
Other operating assets and liabilities (92) (58)
Other 99 51
TOTAL OPERATING ACTIVITIES 14,250 12,597
INVESTING ACTIVITIES
Capital expenditures (2,073) (2,415)
Proceeds from asset sales 40 28
Acquisitions, net of cash acquired — (58)
Purchases of investments securities (10) —
Proceeds from sales and maturities of investment securities — 6,151
Change in other investments — (2)
TOTAL INVESTING ACTIVITIES (2,043) 3,704
FINANCING ACTIVITIES
Dividends to shareholders (6,066) (5,761)
Increases/(reductions) in short-term debt (3,381) 3,020
Additions to long-term debt 2,429 4,951
Reductions to long-term debt (4,889) (1,534)
Treasury stock purchases (8,009) (7,405)
Impact of stock options and other 1,470 1,761
TOTAL FINANCING ACTIVITIES (18,446) (4,968)
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH 65 (179)
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH (6,174) 11,154
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD $ 10,007 $ 15,393
Includes early extinguishment of debt costs of $512 during the nine months ended March 31, 2021.
(1)
(1)
See accompanying Notes to Consolidated Financial Statements.
-- 7 of 53 --
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Basis of Presentation
These statements should be read in conjunction with the Company’s Annual Report on Form 10-K/A for the fiscal year ended June 30, 2020. In the opinion of
management, the accompanying unaudited Consolidated Financial Statements of The Procter & Gamble Company and subsidiaries (the "Company," "Procter &
Gamble," "P&G," "we" or "our") contain all adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim
periods reported. However, the results of operations included in such financial statements may not necessarily be indicative of annual results.
2. New Accounting Pronouncements and Policies
On July 1, 2020, we adopted ASU 2017-04, "Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment." The standard simplifies
the accounting for goodwill impairment by requiring a goodwill impairment to be measured using a single step impairment model, whereby the impairment equals
the difference between the carrying amount and the estimated fair value of the specified reporting units in their entirety. This eliminated the second step of the
previous impairment model that required companies to first estimate the fair value of all assets in a reporting unit and measure impairments based on those
estimated fair values and a residual measurement approach. It also specifies that any loss recognized should not exceed the total amount of goodwill allocated to
that reporting unit. The impact of the new standard will depend on the specific facts and circumstances of future individual impairments, if any.
In March 2020, the FASB issued ASU 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial
Reporting." The amendments provide optional guidance for a limited time to ease the potential burden in accounting for reference rate reform. The new guidance
provides optional expedients and exceptions for applying accounting principles generally accepted in the United States of America (U.S. GAAP) to contracts,
hedging relationships and other transactions affected by reference rate reform if certain criteria are met and to other derivative instruments if there is a change to
the interest rates used for discounting, margining or contract price alignment. These amendments are effective immediately and may be applied prospectively to
contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. We are currently evaluating our contracts and the
optional expedients provided by the new standard.
No other new accounting pronouncement issued or effective during the fiscal year had, or is expected to have, a material impact on our Consolidated Financial
Statements.
3. Segment Information
Under U.S. GAAP, our operating segments are aggregated into five reportable segments: 1) Beauty, 2) Grooming, 3) Health Care, 4) Fabric & Home Care and 5)
Baby, Feminine & Family Care. Our five reportable segments are comprised of:
• Beauty: Hair Care (Conditioners, Shampoos, Styling Aids, Treatments); Skin and Personal Care (Antiperspirants and Deodorants, Personal Cleansing, Skin
Care);
• Grooming: Shave Care (Female Blades & Razors, Male Blades & Razors, Pre- and Post-Shave Products, Other Shave Care); Appliances;
• Health Care: Oral Care (Toothbrushes, Toothpaste, Other Oral Care); Personal Health Care (Gastrointestinal, Rapid Diagnostics, Respiratory,
Vitamins/Minerals/Supplements, Pain Relief, Other Personal Health Care);
• Fabric & Home Care: Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents); Home Care (Air Care, Dish Care, P&G Professional, Surface
Care); and
• Baby, Feminine & Family Care: Baby Care (Baby Wipes, Taped Diapers and Pants); Feminine Care (Adult Incontinence, Feminine Care); Family Care (Paper
Towels, Tissues, Toilet Paper).
Amounts in millions of dollars unless otherwise specified.
-- 8 of 53 --
Our operating segments are comprised of similar product categories. Operating segments that individually accounted for 5% or more of consolidated net sales are
as follows:
% of Net sales by operating segment
Three Months Ended March 31 Nine Months Ended March 31
2021 2020 2021 2020
Fabric Care 23% 23% 22% 23%
Home Care 12% 11% 12% 10%
Baby Care 11% 11% 10% 11%
Skin and Personal Care 9% 9% 10% 10%
Hair Care 9% 9% 9% 9%
Family Care 9% 9% 9% 9%
Oral Care 8% 8% 8% 8%
Shave Care 7% 7% 7% 7%
Feminine Care 6% 7% 6% 6%
Personal Health Care 5% 5% 5% 5%
Other 1% 1% 2% 2%
Total 100% 100% 100% 100%
% of Net sales by operating segment excludes sales held in Corporate.
The following is a summary of reportable segment results:
Three Months Ended March 31 Nine Months Ended March 31
Net Sales
Earnings/(Loss)
Before Income
Taxes Net Earnings Net Sales
Earnings/(Loss)
Before Income
Taxes Net Earnings
Beauty 2021 $ 3,316 $ 721 $ 577 $ 10,907 $ 3,145 $ 2,508
2020 3,033 553 436 10,183 2,717 2,168
Grooming 2021 1,438 314 256 4,774 1,277 1,063
2020 1,380 305 254 4,559 1,225 1,018
Health Care 2021 2,356 484 377 7,573 1,993 1,557
2020 2,262 523 408 7,013 1,795 1,380
Fabric & Home Care 2021 6,275 1,348 1,027 19,417 4,689 3,626
2020 5,826 1,271 957 17,445 3,887 2,960
Baby, Feminine & Family Care 2021 4,604 1,133 871 14,185 3,803 2,924
2020 4,597 1,130 859 13,746 3,340 2,552
Corporate 2021 120 (123) 141 316 (856) (234)
2020 116 (284) 43 306 (591) 239
Total Company 2021 $ 18,109 $ 3,877 $ 3,249 $ 57,172 $ 14,051 $ 11,444
2020 17,214 3,498 2,957 53,252 12,373 10,317
(1)
(1)
Amounts in millions of dollars unless otherwise specified.
-- 9 of 53 --
4. Goodwill and Other Intangible Assets
Goodwill is allocated by reportable segment as follows:
Beauty Grooming Health Care Fabric & Home
Care Baby, Feminine
& Family Care Total Company
Goodwill at June 30, 2020 $ 12,902 $ 12,815 $ 7,786 $ 1,841 $ 4,557 $ 39,901
Translation and other 254 206 159 24 68 711
Goodwill at March 31, 2021 $ 13,156 $ 13,021 $ 7,945 $ 1,865 $ 4,625 $ 40,612
Goodwill increased from June 30, 2020 due to currency translation.
Identifiable intangible assets at March 31, 2021 were comprised of:
Gross Carrying Amount Accumulated Amortization
Intangible assets with determinable lives $ 8,574 $ (6,005)
Intangible assets with indefinite lives 21,089 —
Total identifiable intangible assets $ 29,663 $ (6,005)
Intangible assets with determinable lives consist of brands, patents, technology and customer relationships. The intangible assets with indefinite lives consist of
brands. The amortization expense of determinable-lived intangible assets for the three months ended March 31, 2021 and 2020 was $78 and $87, respectively. For
the nine months ended March 31, 2021 and 2020, the amortization expense was $241 and $274, respectively.
Goodwill and indefinite-lived intangible assets are not amortized but are tested at least annually for impairment by comparing the estimated fair values of our
reporting units and underlying indefinite-lived intangible assets to their respective carrying values. We typically use an income method to estimate the fair value of
these assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. If the resulting fair value is less than the asset's
carrying value, that difference represents an impairment. Our annual impairment testing for goodwill and indefinite-lived intangible assets occurs during the three
months ended December 31.
The business unit valuations used to test goodwill and intangible assets for impairment depend on a number of significant estimates and assumptions, including
macroeconomic conditions, overall category growth rates, competitive activities, cost containment, margin expansion and Company business plans. We believe
these estimates and assumptions are reasonable. However, future changes in the judgments, assumptions and estimates that are used in our impairment testing for
goodwill and indefinite-lived intangible assets, including discount rates, tax rates or future cash flow projections, could result in significantly different estimates of
the fair values. To the extent changes in such factors result in a failure to achieve the level of projected cash flows initially used to estimate fair value for purposes
of establishing or subsequently impairing the carrying amount of goodwill and related intangible assets, we may need to record non-cash impairment charges in the
future.
Most of our goodwill reporting units are comprised of a combination of legacy and acquired businesses and as a result have fair value cushions that, at a minimum,
exceed two times their underlying carrying values. Certain of our goodwill reporting units, in particular Shave Care and Appliances, are comprised entirely of
acquired businesses and as a result, have fair value cushions that are not as high. The Appliances reporting unit has a fair value that significantly exceeds the
underlying carrying value. As previously disclosed, the carrying value of the Shave Care reporting unit and the related Gillette indefinite-lived intangible asset
were impaired during the quarter ended June 30, 2019. Also, as previously disclosed, the Shave Care reporting unit fair value exceeded its carrying value by more
than 20% and the Gillette indefinite-lived intangible asset fair value approximated its carrying value as of our fiscal 2020 impairment testing dates. Based on our
impairment testing during the three months ended December 31, 2020, the Shave Care reporting unit fair value continued to exceed its carrying value by more than
20% and the Gillette indefinite-lived intangible asset's fair value continued to approximate its carrying value.
The most significant assumptions utilized in the determination of the estimated fair values of the Shave Care reporting unit and the Gillette indefinite-lived
intangible asset are the net sales and earnings growth rates (including residual growth rates) and the discount rate. The residual growth rate represents the expected
rate at which the Shave Care reporting unit and Gillette brand are expected to grow beyond the shorter-term business planning period. The residual growth rate
utilized in our fair value estimates is consistent with the reporting unit and brand operating plans and approximates expected long-term category market growth
rates. The residual growth rate depends on overall market growth rates, the competitive environment, inflation, relative currency exchange rates and business
activities that impact market share. As a result, the residual growth rate could be adversely impacted by a sustained deceleration in category growth, grooming
habit changes, devaluation of currencies against the U.S. dollar or an increased competitive environment. The discount rate, which is consistent with a weighted
average cost of capital that is likely to be expected by a market participant, is based upon industry required rates of return, including
Amounts in millions of dollars unless otherwise specified.
-- 10 of 53 --
consideration of both debt and equity components of the capital structure. Our discount rate may be impacted by adverse changes in the macroeconomic
environment, volatility in the equity and debt markets or other country specific factors, such as further devaluation of currencies against the U.S. dollar. Currency
spot rates as of the fair value measurement date are utilized in our fair value estimates for cash flows outside the U.S.
While management can and has implemented strategies to address these events, changes in operating plans or adverse changes in the business or in the
macroeconomic environment in the future could reduce the underlying cash flows used to estimate fair values and could result in a decline in fair value that would
trigger future impairment charges of the Shave Care reporting unit's goodwill and indefinite-lived intangibles. The duration and severity of the COVID-19
pandemic could also result in future impairment charges for the Shave Care reporting unit goodwill and the Gillette indefinite-lived intangible asset. While we have
concluded that a triggering event did not occur during the quarter ended March 31, 2021, the Gillette indefinite-lived intangible asset is most susceptible to future
impairment risk. Our assessment of the Gillette intangible asset assumes the pandemic’s impact on net sales growth rates will be largely eliminated by the end of
the fiscal year. There continues to be a high level of uncertainty relating to how the pandemic will evolve, how governments and consumers will react and progress
on the distribution of vaccines. Accordingly, there continues to be risk related to this key assumption. A more prolonged pandemic recovery period could impact
the assumptions utilized in the determination of the estimated fair values of the Shave Care reporting unit and the Gillette indefinite-lived intangible asset that are
significant enough to trigger an impairment. Net sales and earnings growth rates could be negatively impacted by reductions or changes in demand for our shave
care products, which may be caused by, among other things: the temporary inability of consumers to purchase our products due to illness, quarantine or other travel
restrictions, or financial hardship, or by shifts in demand away from one or more of our higher priced products to lower priced products. In addition, relative global
and country/regional macroeconomic factors could result in additional and prolonged devaluation of other countries’ currencies relative to the U.S. dollar. Finally,
the discount rate utilized in our valuation model could be impacted by changes in the underlying interest rates and risk premiums included in the determination of
the cost of capital. As of March 31, 2021, the carrying values of the Shave Care goodwill and the Gillette indefinite-lived intangible asset were $12.7 billion and
$14.1 billion, respectively.
We performed a sensitivity analysis for the Shave Care reporting unit and the Gillette indefinite-lived intangible asset during our annual impairment testing,
utilizing reasonably possible changes in the assumptions for the shorter-term and residual growth rates and the discount rate, to demonstrate the potential impacts to
the estimated fair values. The table below provides, in isolation, the estimated fair value impacts related to a 25 basis-point increase in the discount rate or a 25
basis-point decrease in our shorter-term and residual growth rates, either of which, in isolation, would result in an impairment of the Gillette indefinite-lived
intangible asset.
Approximate Percent Change in Estimated Fair Value
+25 bps Discount Rate -25 bps Growth Rates
Shave Care goodwill reporting unit (6) % (6) %
Gillette indefinite-lived intangible asset (6) % (6) %
Amounts in millions of dollars unless otherwise specified.
-- 11 of 53 --
5. Earnings Per Share
Basic net earnings per common share are calculated by dividing Net earnings attributable to Procter & Gamble less preferred dividends (net of related tax benefits)
by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share are calculated by dividing Net earnings
attributable to Procter & Gamble by the diluted weighted average number of common shares during the period. The diluted shares include the dilutive effect of
stock options and other stock-based awards based on the treasury stock method and the assumed conversion of preferred stock.
Net earnings per share were calculated as follows:
CONSOLIDATED AMOUNTS Three Months Ended March 31 Nine Months Ended March 31
2021 2020 2021 2020
Net earnings $ 3,249 $ 2,957 $ 11,444 $ 10,317
Less: Net earnings/(loss) attributable to noncontrolling interests (20) 40 44 90
Net earnings attributable to P&G (Diluted) 3,269 2,917 11,400 10,227
Less: Preferred dividends, net of tax 65 64 197 193
Net earnings attributable to P&G available to common shareholders (Basic) $ 3,204 $ 2,853 $ 11,203 $ 10,034
SHARES IN MILLIONS
Basic weighted average common shares outstanding 2,459.1 2,476.2 2,473.7 2,489.1
Add: Effect of dilutive securities
Conversion of preferred shares 82.3 85.5 83.1 86.4
Impact of stock options and other unvested equity awards 48.9 51.6 53.6 54.8
Diluted weighted average common shares outstanding 2,590.3 2,613.3 2,610.4 2,630.3
NET EARNINGS PER SHARE
Basic $ 1.30 $ 1.15 $ 4.53 $ 4.03
Diluted $ 1.26 $ 1.12 $ 4.37 $ 3.89
Despite being included currently in Diluted net earnings per common share, the actual conversion to common stock occurs when the preferred shares are sold.
Shares may only be sold after being allocated to the ESOP participants pursuant to the repayment of the ESOP's obligations through 2035.
Weighted average outstanding stock options of approximately 12 million and 7 million for the three months ended March 31, 2021 and 2020, and
approximately 8 million and 3 million for the nine months ended March 31, 2021 and 2020, respectively, were not included in the Diluted net earnings per
share calculation because the options were out of the money or to do so would have been antidilutive (i.e., the total proceeds upon exercise would have
exceeded the market value of the underlying common shares).
Net earnings per share are calculated on Net earnings attributable to Procter & Gamble.
6. Share-Based Compensation and Postretirement Benefits
The following table provides a summary of our share-based compensation expense and postretirement benefit costs:
Three Months Ended March 31 Nine Months Ended March 31
2021 2020 2021 2020
Share-based compensation expense $ 144 $ 123 $ 398 $ 325
Net periodic benefit cost for pension benefits 48 42 141 126
Net periodic benefit credit for other retiree benefits (80) (52) (240) (156)
The components of the total net periodic benefit cost/(credit) for both pension benefits and other retiree benefits for these interim periods, on an annualized
basis, do not differ materially from the amounts disclosed in the Annual Report on Form 10-K/A for the fiscal year ended June 30, 2020.
(1)
(2)
(3)
(1)
(2)
(3)
(1)
(1)
(1)
Amounts in millions of dollars unless otherwise specified.
-- 12 of 53 --
7. Risk Management Activities and Fair Value Measurements
As a multinational company with diverse product offerings, we are exposed to market risks, such as changes in interest rates, currency exchange rates and
commodity prices. There have been no significant changes in our risk management policies or activities during the nine months ended March 31, 2021.
The Company has not changed its valuation techniques used in measuring the fair value of any financial assets and liabilities during the period. The Company
recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers between levels during the periods
presented. Also, there was no significant activity within the Level 3 assets and liabilities during the periods presented. There were no significant assets or liabilities
that were remeasured at fair value on a non-recurring basis for the nine months ended March 31, 2021.
Cash equivalents were $8.5 billion and $14.6 billion as of March 31, 2021 and June 30, 2020, respectively, and are classified as Level 1 within the fair value
hierarchy. Other investments had a fair value of $132 and $67 as of March 31, 2021 and June 30, 2020, respectively, including equity securities of $104 and $39 as
of March 31, 2021 and June 30, 2020, respectively, and are presented in Other noncurrent assets. Investments are measured at fair value and primarily classified as
Level 1 and Level 2 within the fair value hierarchy. Level 1 are based on quoted market prices in active markets for identical assets, and Level 2 are based on
quoted market prices for similar instruments. There are no material investment balances classified as Level 3 within the fair value hierarchy or using net asset value
as a practical expedient. Unrealized gains on equity securities were $58 during the three and nine months ended March 31, 2021 and not significant for the three
and nine months ended March 31, 2020. These unrealized gains are recognized in the Consolidated Statements of Earnings in Other non-operating
income/(expense), net.
The fair value of long-term debt was $26.4 billion and $29.0 billion as of March 31, 2021 and June 30, 2020, respectively. This includes the current portion of
long-term debt instruments ($3.6 billion and $2.5 billion as of March 31, 2021 and June 30, 2020, respectively). Certain long-term debt (debt designated as a fair
value hedge) is recorded at fair value. All other long-term debt is recorded at amortized cost but is measured at fair value for disclosure purposes. We consider our
debt to be Level 2 in the fair value hierarchy. Fair values are generally estimated based on quoted market prices for identical or similar instruments.
Disclosures about Financial Instruments
The notional amounts and fair values of financial instruments used in hedging transactions as of March 31, 2021 and June 30, 2020 are as follows:
Notional Amount Fair Value Asset Fair Value (Liability)
March 31, 2021 June 30, 2020 March 31, 2021 June 30, 2020 March 31, 2021 June 30, 2020
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS
Interest rate contracts $ 7,327 $ 7,114 $ 174 $ 269 $ — $ —
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS
Foreign currency interest rate contracts $ 7,375 $ 3,856 $ 97 $ 26 $ (92) $ (41)
TOTAL DERIVATIVES DESIGNATED AS HEDGING
INSTRUMENTS $ 14,702 $ 10,970 $ 271 $ 295 $ (92) $ (41)
DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS
Foreign currency contracts $ 6,375 $ 5,986 $ 7 $ 23 $ (70) $ (25)
TOTAL DERIVATIVES AT FAIR VALUE $ 21,077 $ 16,956 $ 278 $ 318 $ (162) $ (66)
The fair value of the interest rate derivative asset/(liability) directly offsets the cumulative amount of the fair value hedging adjustment included in the carrying
amount of the underlying debt obligation. The carrying amount of the underlying debt obligation, which includes the unamortized discount or premium and the fair
value adjustment, was $7.5 billion and $7.4 billion as of March 31, 2021 and June 30, 2020, respectively. In addition to the foreign currency derivative contracts
designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as net investment hedges. The carrying value of
those debt instruments designated as net investment hedges, which includes the adjustment for the foreign currency transaction gain or loss on those instruments,
was $11.8 billion and $16.0 billion as of March 31, 2021 and June 30, 2020, respectively. The increase in the notional balance of derivative instruments designated
as net investment hedges is offset by the decrease in the principal balance of debt instruments designated as net investment hedges, reflecting the Company’s
decision to leverage favorable interest rates in the foreign currency swap market versus the short-term debt market.
All derivative assets are presented in Prepaid expenses and other current assets or Other noncurrent assets. All derivative liabilities are presented in Accrued and
other liabilities or Other noncurrent liabilities. Changes in the fair value of net
Amounts in millions of dollars unless otherwise specified.
-- 13 of 53 --
investment hedges are recognized in the Foreign currency translation component of Other comprehensive income (OCI). All of the Company's derivative assets and
liabilities measured at fair value are classified as Level 2 within the fair value hierarchy.
Before tax gains/(losses) on our financial instruments in hedging relationships are categorized as follows:
Amount of Gain/(Loss) Recognized in OCI on Derivatives
Three Months Ended March 31 Nine Months Ended March 31
2021 2020 2021 2020
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS
Foreign exchange contracts $ 393 $ 83 $ (145) $ 114
For the derivatives in net investment hedging relationships, the amount of gain excluded from effectiveness testing, which was recognized in earnings, was $15
and $17 for the three months ended March 31, 2021 and 2020, respectively. The amount of gain excluded from effectiveness testing was $45 and $57 for the
nine months ended March 31, 2021 and 2020, respectively.
In addition to the foreign currency derivative contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are
designated as net investment hedges. The amount of gain recognized in Accumulated other comprehensive income/(loss) (AOCI) for such instruments was
$509 and $306 for the three months ended March 31, 2021 and 2020, respectively. The amount of gain/(loss) recognized in AOCI for such instruments was
$(732) and $487 for the nine months ended March 31, 2021 and 2020, respectively.
Amount of Gain/(Loss) Recognized in Earnings
Three Months Ended March 31 Nine Months Ended March 31
2021 2020 2021 2020
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS
Interest rate contracts $ (100) $ 109 $ (95) $ 56
DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS
Foreign currency contracts $ (87) $ (148) $ 221 $ (160)
The gain/(loss) on the derivatives in fair value hedging relationships is fully offset by the mark-to-market impact of the related exposure. These are both recognized
in the Consolidated Statements of Earnings in Interest expense. The gain/(loss) on derivatives not designated as hedging instruments is substantially offset by the
currency mark-to-market of the related exposure. These are both recognized in the Consolidated Statements of Earnings in Selling, general and administrative
expense (SG&A).
8. Accumulated Other Comprehensive Income/(Loss)
The table below presents the changes in AOCI, including the reclassifications out of AOCI by component:
Investment
Securities Post-retirement
Benefits Foreign Currency
Translation Total AOCI
Balance at June 30, 2020 $ (1) $ (4,350) $ (11,814) $ (16,165)
OCI before reclassifications 17 (225) 639 431
Amounts reclassified from AOCI into the Consolidated Statements of Earnings 2 249 — 251
Net current period OCI 19 24 639 682
Less: Other comprehensive income/(loss) attributable to non-controlling interests — (1) 7 6
Balance at March 31, 2021 $ 18 $ (4,325) $ (11,182) $ (15,489)
Net of tax expense/(benefit) of $0, $(65) and $(206) for gains/losses on investment securities, postretirement benefit items and foreign currency translation,
respectively.
Net of tax expense/(benefit) of $0, $77 and $0 for gains/losses on investment securities, postretirement benefit items and foreign currency translation,
respectively.
The below provides additional details on amounts reclassified from AOCI into the Consolidated Statements of Earnings:
• Investment securities: amounts reclassified from AOCI into Other non-operating income, net.
• Postretirement benefits: amounts reclassified from AOCI into Other non-operating income, net and included in the computation of net periodic
postretirement costs.
(1) (2)
(1)
(2)
(1)
(2)
(1)
(2)
Amounts in millions of dollars unless otherwise specified.
-- 14 of 53 --
9. Restructuring Program
The Company has historically incurred an ongoing annual level of restructuring-type activities to maintain a competitive cost structure, including manufacturing
and workforce optimization. Before-tax costs incurred under the ongoing program have generally ranged from $250 to $500 annually.
In fiscal 2017, the Company announced specific elements of an additional multi-year productivity and cost savings plan to further reduce costs in the areas of
supply chain, certain marketing activities and overhead expenses, which resulted in incremental restructuring charges through fiscal 2020. We expect fiscal 2021
restructuring charges to be more in line with our ongoing level of spending noted above.
Restructuring costs incurred consist primarily of costs to separate employees, asset-related costs to exit facilities and other costs. Employee separation costs relate
to severance packages that were primarily voluntary, and the amounts were calculated based on salary levels and past service periods. Severance costs related to
voluntary separations are generally charged to earnings when the employee accepts the offer. Asset-related costs consist of both asset write-downs and accelerated
depreciation. Asset write-downs relate to the establishment of a new fair value basis for assets held-for-sale or disposal. These assets were written down to the
lower of their current carrying basis or amounts expected to be realized upon disposal, less minor disposal costs. Charges for accelerated depreciation relate to
long-lived assets that will be taken out of service prior to the end of their normal service period. These assets relate primarily to manufacturing consolidations and
technology standardizations. The asset-related charges will not have a significant impact on future depreciation charges. Other restructuring-type charges are
incurred as a direct result of the restructuring program. Such charges primarily include asset removal and termination of contracts related to supply chain and
overhead optimization.
The following table presents restructuring activity for the three and nine months ended March 31, 2021. The majority of the remaining reserve balance as of March
31, 2021 relates to employee separations.
Reserve Balance
Previously Reported (Six
Months Ended
December 31, 2020) Three Months Ended March
31, 2021
Nine Months Ended March
31, 2021 Reserve Balance
June 30, 2020 Cost Incurred and Charged
to Expense
Cost Incurred and Charged to
Expense Cost Paid/Settled March 31, 2021
Total $ 472 $ 87 $ 134 $ (423) $ 270
10. Commitments and Contingencies
Litigation
We are subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including antitrust and
trade regulation, product liability, advertising, contracts, environmental, patent and trademark matters, labor and employment matters and tax. While considerable
uncertainty exists, in the opinion of management and our counsel, the ultimate resolution of the various lawsuits and claims will not materially affect our financial
position, results of operations or cash flows.
We are also subject to contingencies pursuant to environmental laws and regulations that in the future may require us to take action to correct the effects on the
environment of prior manufacturing and waste disposal practices. Based on currently available information, we do not believe the ultimate resolution of
environmental remediation will materially affect our financial position, results of operations or cash flows.
Income Tax Uncertainties
The Company is present in approximately 70 countries and over 150 taxable jurisdictions and, at any point in time, has 40–50 jurisdictional audits underway at
various stages of completion. We evaluate our tax positions and establish liabilities for uncertain tax positions that may be challenged by local authorities and may
not be fully sustained, despite our belief that the underlying tax positions are fully supportable. Uncertain tax positions are reviewed on an ongoing basis and are
adjusted in light of changing facts and circumstances, including progress of tax audits, developments in case law and closing of statutes of limitations. Such
adjustments are reflected in the tax provision as appropriate. We have tax years open ranging from 2008 and forward. We are generally not able to reliably estimate
the ultimate settlement amounts until the close of the audit. Based on information currently available, we anticipate that over the next 12 month period, audit
activity could be completed related to uncertain tax positions in multiple jurisdictions for which we have accrued existing liabilities of approximately $60,
including interest and penalties.
Additional information on the Commitments and Contingencies of the Company can be found in our Annual Report on Form 10-K/A for the year ended June 30,
2020.
Amounts in millions of dollars unless otherwise specified.
-- 15 of 53 --
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Forward-Looking Statements
Certain statements in this report, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and
expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements may appear throughout this report, including, without limitation, the following sections: “Management's Discussion and Analysis,” “Risk Factors,” and
"Notes 4 and 10 to the Consolidated Financial Statements." These forward-looking statements generally are identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and
similar expressions. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and uncertainties that may cause
results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise publicly any forward-
looking statements, whether because of new information, future events or otherwise, except to the extent required by law.
Risks and uncertainties to which our forward-looking statements are subject include, without limitation: (1) the ability to successfully manage global financial
risks, including foreign currency fluctuations, currency exchange or pricing controls and localized volatility; (2) the ability to successfully manage local, regional
or global economic volatility, including reduced market growth rates, and to generate sufficient income and cash flow to allow the Company to affect the expected
share repurchases and dividend payments; (3) the ability to manage disruptions in credit markets or changes to our credit rating; (4) the ability to maintain key
manufacturing and supply arrangements (including execution of supply chain optimizations and sole supplier and sole manufacturing plant arrangements) and to
manage disruption of business due to factors outside of our control, such as natural disasters, acts of war or terrorism, or disease outbreaks; (5) the ability to
successfully manage cost fluctuations and pressures, including prices of commodities and raw materials, and costs of labor, transportation, energy, pension and
healthcare; (6) the ability to stay on the leading edge of innovation, obtain necessary intellectual property protections and successfully respond to changing
consumer habits and technological advances attained by, and patents granted to, competitors; (7) the ability to compete with our local and global competitors in
new and existing sales channels, including by successfully responding to competitive factors such as prices, promotional incentives and trade terms for products;
(8) the ability to manage and maintain key customer relationships; (9) the ability to protect our reputation and brand equity by successfully managing real or
perceived issues, including concerns about safety, quality, ingredients, efficacy or similar matters that may arise; (10) the ability to successfully manage the
financial, legal, reputational and operational risk associated with third-party relationships, such as our suppliers, contract manufacturers, distributors, contractors
and external business partners; (11) the ability to rely on and maintain key company and third party information and operational technology systems, networks and
services, and maintain the security and functionality of such systems, networks and services and the data contained therein; (12) the ability to successfully manage
uncertainties related to changing political conditions (including the United Kingdom’s exit from the European Union) and potential implications such as exchange
rate fluctuations and market contraction; (13) the ability to successfully manage regulatory and legal requirements and matters (including, without limitation, those
laws and regulations involving product liability, product and packaging composition, intellectual property, labor and employment, antitrust, data protection, tax,
environmental, and accounting and financial reporting) and to resolve pending matters within current estimates; (14) the ability to manage changes in applicable
tax laws and regulations including maintaining our intended tax treatment of divestiture transactions; (15) the ability to successfully manage our ongoing
acquisition, divestiture and joint venture activities, in each case to achieve the Company’s overall business strategy and financial objectives, without impacting the
delivery of base business objectives; (16) the ability to successfully achieve productivity improvements and cost savings and manage ongoing organizational
changes, while successfully identifying, developing and retaining key employees, including in key growth markets where the availability of skilled or experienced
employees may be limited; and (17) the ability to successfully manage the demand, supply, and operational challenges associated with a disease outbreak,
including epidemics, pandemics, or similar widespread public health concerns (including the novel coronavirus, COVID-19, outbreak). A detailed discussion of
risks and uncertainties that could cause actual results and events to differ materially from those projected herein, is included in the section titled "Economic
Conditions and Uncertainties" and the section titled "Risk Factors" (Part II, Item 1A) of this Form 10-Q.
The purpose of Management's Discussion and Analysis (MD&A) is to provide an understanding of Procter & Gamble's financial condition, results of operations
and cash flows by focusing on changes in certain key measures from year to year. The MD&A is provided as a supplement to, and should be read in conjunction
with, our Consolidated Financial Statements and accompanying Notes.
The MD&A is organized in the following sections:
• Overview
• Summary of Results – Nine Months Ended March 31, 2021
• Economic Conditions and Uncertainties
• Results of Operations – Three and Nine Months Ended March 31, 2021
• Business Segment Discussion – Three and Nine Months Ended March 31, 2021
• Liquidity and Capital Resources
• Reconciliation of Measures Not Defined by U.S. GAAP
Throughout the MD&A, we refer to measures used by management to evaluate performance, including unit volume growth, net sales and net earnings. We also
refer to a number of financial measures that are not defined under accounting principles generally accepted in the United States of America (U.S. GAAP),
consisting of organic sales growth, core net earnings per share (Core EPS), adjusted free cash flow and adjusted free cash flow productivity. The explanation at the
end of the MD&A provides the definition of these non-GAAP measures, details on the use and the derivation of these measures, as well as reconciliations to the
most directly comparable U.S. GAAP measures.
Management also uses certain market share and market consumption estimates to evaluate performance relative to competition despite some limitations on the
availability and comparability of share and consumption information. References to market share and market consumption in the MD&A are based on a
combination of vendor purchased traditional brick-and-mortar and online data in key markets as well as internal estimates. All market share references represent
the percentage of sales of our products in dollar terms on a constant currency basis, relative to all product sales in the category. The Company measures fiscal year
to date market shares through the most recent period for which market share data is available, which typically reflects a lag time of one or two months as compared
to the end of the reporting period. Management also uses unit volume growth to evaluate and explain drivers of changes in net sales. Organic volume growth
-- 16 of 53 --
reflects year-over-year changes in unit volume excluding the impacts of acquisitions and divestitures and certain one-time items if applicable and is used to explain
changes in organic sales.
OVERVIEW
P&G is a global leader in the fast-moving consumer goods industry, focused on providing branded consumer packaged goods of superior quality and value to our
consumers around the world. Our products are sold in more than 180 countries and territories, primarily through mass merchandisers, e-commerce, grocery stores,
membership club stores, drug stores, department stores, distributors, wholesalers, baby stores, specialty beauty stores (including airport duty-free stores), high-
frequency stores, pharmacies, electronics stores and professional channels. We also sell direct to consumers. We have on-the-ground operations in approximately
70 countries.
Our market environment is highly competitive with global, regional and local competitors. In many of the markets and industry segments in which we sell our
products, we compete against other branded products as well as retailers' private-label brands. Additionally, many of the product segments in which we compete
are differentiated by price tiers (referred to as super-premium, premium, mid-tier and value-tier products). We believe we are well positioned in the industry
segments and markets in which we operate, often holding a leadership or significant market share position.
The table below provides detail on our reportable segments, including the product categories and brand composition within each segment.
Reportable Segments Product Categories (Sub-Categories) Major Brands
Beauty
Hair Care (Conditioners, Shampoos, Styling Aids, Treatments) Head & Shoulders, Herbal
Essences, Pantene, Rejoice
Skin and Personal Care (Antiperspirants and Deodorants, Personal Cleansing, Skin
Care) Olay, Old Spice, Safeguard,
Secret, SK-II
Grooming Grooming (Shave Care - Female Blades & Razors, Male Blades & Razors, Pre- and
Post-Shave Products, Other Shave Care; Appliances) Braun, Gillette, Venus
Health Care
Oral Care (Toothbrushes, Toothpastes, Other Oral Care) Crest, Oral-B
Personal Health Care (Gastrointestinal, Rapid Diagnostics, Respiratory,
Vitamins/Minerals/Supplements, Pain Relief, Other Personal Health Care)
Metamucil, Neurobion, Pepto-
Bismol, Vicks
Fabric & Home Care
Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents) Ariel, Downy, Gain, Tide
Home Care (Air Care, Dish Care, P&G Professional, Surface Care) Cascade, Dawn, Fairy, Febreze,
Mr. Clean, Swiffer
Baby, Feminine & Family Care
Baby Care (Baby Wipes, Taped Diapers and Pants) Luvs, Pampers
Feminine Care (Adult Incontinence, Feminine Care) Always, Always Discreet,
Tampax
Family Care (Paper Towels, Tissues, Toilet Paper) Bounty, Charmin, Puffs
The Grooming product category is comprised of the Shave Care and Appliances operating segments.
The following table provides the percentage of net sales and net earnings by reportable business segment for the three and nine months ended March 31, 2021
(excluding net sales and net earnings in Corporate):
Three Months Ended March 31, 2021 Nine Months Ended March 31, 2021
Net Sales Net Earnings Net Sales Net Earnings
Beauty 18% 19% 19% 22%
Grooming 8% 8% 9% 9%
Health Care 13% 12% 13% 13%
Fabric & Home Care 35% 33% 34% 31%
Baby, Feminine & Family Care 26% 28% 25% 25%
Total Company 100% 100% 100% 100%
SUMMARY OF RESULTS
The following are highlights of results for the nine months ended March 31, 2021 versus the nine months ended March 31, 2020:
• Net sales increased 7% to $57.2 billion, driven by double digit increase in Fabric & Home Care, high single digit increases in Beauty and Health Care, mid-
single digits increase in Grooming and low single digits increase in Baby, Feminine & Family Care. Organic sales, which exclude the impacts of acquisitions
and divestitures and foreign exchange, also increased 7%. Organic sales increased double digits in Fabric & Home Care, increased high single digits in Health
Care, increased mid-single digits in Beauty and Grooming and increased low single digits in Baby, Feminine & Family Care.
• Net earnings were $11.4 billion, an increase of $1.1 billion or 11% versus the prior year period due to the increase in net sales and an increase in operating
margins, partially offset by an increase in the effective tax rate and current year charges of $512 million for early debt extinguishment.
• Net earnings attributable to Procter & Gamble increased $1.2 billion or 11% versus the prior year period to $11.4 billion.
• Diluted net earnings per share (EPS) increased 12% to $4.37 due primarily to the increase in net earnings.
• Core net earnings attributable to Procter & Gamble, which represents net earnings excluding charges for the early extinguishment of debt in the current period
and incremental restructuring charges in the base period, increased 14% to $11.8 billion. Core net earnings per share increased 14% to $4.53 versus the prior
year due primarily to the increase in Core net earnings.
• Operating cash flow was $14.3 billion. Adjusted free cash flow, which is operating cash flow less capital expenditures and certain other impacts, was $12.4
billion. Adjusted free cash flow productivity was 104%.
ECONOMIC CONDITIONS AND UNCERTAINTIES
Global Economic Conditions. Our products are sold in numerous countries across North America, Europe, Latin America, Asia and Africa with more than half
our sales generated outside the United States. As such, we are exposed to and impacted by global macro-economic factors, U.S. and foreign government policies
and foreign exchange fluctuations. Current global economic conditions are highly volatile due to the COVID-19 pandemic, resulting in both market size
contractions in certain countries due to economic slowdowns and government restrictions on movement, as well as market size increases in certain countries due to
(1)
(1)
-- 17 of 53 --
contractions in certain countries due to economic slowdowns and government restrictions on movement, as well as market size increases in certain countries due to
increased consumption of household cleaning and personal health and hygiene products by consumers. Other macro-economic factors also remain dynamic, and
any causes of market size contraction, such as reduced GDP in commodity-dependent economies, greater political unrest or instability in the Middle East, Central
& Eastern Europe, certain Latin American markets, the Hong Kong market in Greater China and the Korean peninsula could reduce our net sales or erode our
operating margin, in either case reducing our net earnings and cash flows.
Changes in Costs. Our costs are subject to fluctuations, particularly due to changes in commodity prices, transportation costs and our own productivity efforts. We
have significant exposures to certain commodities, in particular, certain oil-derived materials like resins and paper-based materials like pulp, and volatility in the
market price of these commodity input materials has a direct impact on our costs. Disruptions in our manufacturing, supply and distribution operations due to the
COVID-19 pandemic may also impact our costs. If we are unable to manage these impacts through pricing actions, cost savings projects and sourcing decisions, as
well as through consistent productivity improvements, it may adversely impact our gross margin, operating margin, net earnings and cash flows. Net sales could
also be adversely impacted following pricing actions if there is a negative impact on consumption of our products. We strive to implement, achieve and sustain cost
improvement plans, including outsourcing projects, supply chain optimization and general overhead and workforce optimization. In fiscal 2017, we communicated
specific elements of a multi-year cost reduction program which has resulted in targeted enrollment reductions and other savings. If we are not successful in
executing and sustaining these changes, there could be a negative impact on our gross margin, operating margin, net earnings and cash flows.
Foreign Exchange. We have both translation and transaction exposure to the fluctuation of exchange rates. Translation exposures relate to exchange rate impacts
of measuring income statements of foreign subsidiaries that do not use the U.S. dollar as their functional currency. Transaction exposures relate to 1) the impact
from input costs that are denominated in a currency other than the local reporting currency and 2) the revaluation of transaction-related working capital balances
denominated in currencies other than the functional currency. In the past two fiscal years, as well as the current fiscal year, the U.S. dollar has strengthened versus
a number of foreign currencies, leading to lower sales and earnings from these foreign exchange impacts. Certain countries experiencing significant exchange rate
fluctuations, like Argentina, Brazil, Russia, Turkey, the United Kingdom, China as well as the European Union have previously had, and could in the future have, a
significant impact on our net sales, costs and net earnings. Increased pricing in response to certain fluctuations in foreign currency exchange rates may offset
portions of the currency impacts but could also have a negative impact on consumption of our products, which would affect our net sales, gross margin, operating
margin, net earnings and cash flows.
Government Policies. Our net earnings and cash flows could be materially affected by changes in U.S. or foreign government legislative, regulatory or
enforcement policies. For example, any future tax regulatory guidance issued as a result of the Tax Cuts and Jobs Act enacted in December 2017 (the U.S. Tax Act)
or other changes in U.S. tax policies, or any significant change in global tax policy adopted under the current work being led by the OECD for the G20 focused on
"Addressing the Challenges of the Digitalization of the Economy." The breadth of the OECD project extends beyond pure digital businesses and is likely to impact
all multinational businesses by redefining jurisdictional taxation rights. Further, our net sales, gross margin, operating margin, net earnings and cash flows may be
impacted by changes in U.S. and foreign government policies related to environmental and climate change matters. Additionally, we attempt to carefully manage
our debt, currency and other exposures in certain countries with currency exchange, import authorization and pricing controls, such as Nigeria, Algeria, Egypt,
Argentina and Turkey. Further, our net sales, gross margin, operating margin, net earnings and cash flows could be affected by changes to international trade
agreements in North America and elsewhere, including increases of import tariffs, both currently effective and future potential changes. Changes in government
policies in these areas might cause an increase or decrease in our net sales, gross margin, operating margin, net earnings and cash flows.
COVID-19 Pandemic Disclosures. Our net sales, net earnings and cash flows may be impacted by U.S. and foreign government policies to manage the COVID-
19 pandemic, such as movement restrictions or site closures. The Company’s priorities during the COVID-19 pandemic continue to be protecting the health and
safety of our employees; maximizing the availability of products that help consumers with their health, hygiene and cleaning needs; and, using our employees’
talents and our resources to help society meet and overcome the current challenges. Because the Company sells products that are essential to the daily lives of
consumers, the COVID-19 pandemic has not had a materially negative impact to our consolidated net sales, gross margin, operating margin, net earnings and cash
flows. The pandemic has had both positive and negative impacts to our net sales and net earnings during the three and nine month periods ended March 31, 2021.
We have experienced
a significant increase in demand and consumption of certain of our product categories (fabric, home cleaning and hygiene products) primarily in North America,
caused in part by changing consumer habits, pantry stocking and retailer inventory replenishment, due to the COVID-19 pandemic, contributing to increases in net
sales, net earnings and cash flows. At the same time, we experienced a decrease in net sales due to the economic slowdown and restricted consumer movements in
certain regions, including IMEA (India, Middle East and Africa) and Asia Pacific, in certain channels, including travel retail and professional, and in certain of our
beauty and grooming products. In the future, the pandemic may cause reduced demand for our products if it results in a recessionary global economic environment.
Demand in certain countries in Latin America, Asia Pacific, and IMEA may be particularly susceptible to recession. It could also lead to volatility in consumer
access to our products due to government actions impacting our ability to produce and ship products or impacting consumers’ movements and access to our
products. We believe that over the long term, there will continue to be strong demand for categories in which we operate, particularly our products that deliver
essential health, hygiene and cleaning benefits. However, the timing and extent of demand recovery in certain markets in Asia Pacific, IMEA and Latin America,
the resumption of international travel, the timing and impact of potential consumer pantry destocking in markets including North America and Europe, and product
demand volatility caused by future economic trends are unclear. Accordingly, there may be heightened volatility in net sales, net earnings and cash flows during
and subsequent to the duration of the pandemic. Our retail customers are also being impacted by the pandemic. Their success in addressing the issues and
maintaining their operations could impact consumer access to, and as a result, sales of our products.
Our ability to continue to operate without any significant negative impacts will in part depend on our ability to protect our employees and our supply chain. The
Company has endeavored to follow actions recommended by governments and health authorities, including on vaccine administration, to protect our employees
world-wide, with particular measures in place for those working in our plants and distribution facilities. We have also worked closely with local and national
officials to keep our manufacturing facilities open due to the essential nature of the majority of our products. While we have been able to broadly maintain our
operations, we experienced some disruption in our supply chain in certain markets in Asia Pacific and IMEA in the first months of the pandemic due primarily to
the restriction of employee movements as well as increased transportation and manufacturing costs. We intend to continue to work with government authorities and
implement our employee safety measures to ensure that we continue manufacturing and distributing our products during the pandemic. However, uncertainty
resulting from the pandemic could result in an unforeseen disruption to our supply chain (for example, a closure of a key manufacturing or distribution facility or
the inability of a key material or transportation supplier to source and transport materials) that could impact our operations.
Because the pandemic has not had a material negative impact on our operations or demand for our products and resulting net sales and net earnings, it has also not
negatively impacted the Company’s liquidity position. We continue to generate operating cash flows to meet our short-term liquidity needs, and we have
maintained access to the capital markets enabled by our strong short- and long-term credit ratings. We have also not observed any material impairments of our
assets or a significant change in the fair value of assets due to the COVID-19 pandemic.
For additional information on risk factors that could impact our results, please refer to “Risk Factors” in Part I, Item 1A of the Company's Form 10-K/A for the
fiscal year ended June 30, 2020.
RESULTS OF OPERATIONS – Three Months Ended March 31, 2021
The following discussion provides a review of results for the three months ended March 31, 2021 versus the three months ended March 31, 2020.
-- 18 of 53 --
Three Months Ended March 31
Amounts in millions, except per share amounts 2021 2020 % Chg
Net sales $18,109 $17,214 5%
Operating income 3,785 3,453 10%
Net earnings 3,249 2,957 10%
Net earnings attributable to Procter & Gamble 3,269 2,917 12%
Diluted net earnings per common share 1.26 1.12 13%
Core net earnings per common share 1.26 1.17 8%
Three Months Ended March 31
COMPARISONS AS A PERCENTAGE OF NET SALES 2021 2020 Basis Pt Chg
Gross margin 50.7% 49.4% 130
Selling, general & administrative expense 29.8% 29.3% 50
Operating income 20.9% 20.1% 80
Earnings before income taxes 21.4% 20.3% 110
Net earnings 17.9% 17.2% 70
Net earnings attributable to Procter & Gamble 18.1% 16.9% 120
Net Sales
Net sales for the quarter increased 5% to $18.1 billion while unit volume was unchanged. Increased pricing had a 2% positive impact to net sales. Mix had a 2%
positive impact to net sales, driven by the disproportionate growth of the North America region, the Home Care, Appliances and Oral Care businesses, and super
premium products within Skin and Personal Care, all of which have higher than company-average selling prices. Favorable foreign exchange had a 1% positive
impact on net sales. Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales increased 4% while organic volume was unchanged.
Net sales increased high single digits in Beauty and Fabric & Home Care, increased mid-single digits in Grooming and Health Care and was unchanged in Baby,
Feminine & Family Care. On a regional basis, volume increased double digits in Greater China and increased low single digits in North America and IMEA,
partially offset by a mid-single digits decrease in Europe and a low single digit decrease in Asia Pacific. Volume was unchanged in Latin America.
Net Sales Change Drivers 2021 vs. 2020 (Three Months Ended March 31)
Volume with
Acquisitions &
Divestitures
Volume Excluding
Acquisitions &
Divestitures Foreign
Exchange Price Mix Other Net Sales
Growth
Beauty 2% 2% 2% 2% 3% —% 9%
Grooming —% —% —% 2% 2% —% 4%
Health Care —% —% 1% —% 3% —% 4%
Fabric & Home Care 3% 3% 1% 2% 2% —% 8%
Baby, Feminine & Family Care (4)% (4)% 1% 2% 1% —% —%
Total Company —% —% 1% 2% 2% —% 5%
Net sales percentage changes are approximations based on quantitative formulas that are consistently applied.
Other includes the sales mix impact from acquisitions and divestitures and rounding impacts necessary to reconcile volume to net sales.
Operating Costs
Gross margin increased 130 basis points to 50.7% of net sales for the quarter. Gross margin benefited from:
• 120 basis points of gross manufacturing cost savings projects (90 basis points net of product and packaging reinvestments),
• 80 basis points of help from higher pricing, and
• 100 basis points of help due to lower restructuring costs versus the base period
These benefits were partially offset by a 60 basis point decline from unfavorable mix (due to the disproportionate growth of the Home Care and Appliances
categories which have lower than company-average margins) and other impacts, a 50 basis-point decline from unfavorable foreign exchange and a 30 basis-point
decline due to higher commodity costs.
Total SG&A spending increased 7% to $5.4 billion due to increases in both marketing spending and overhead costs. SG&A as a percentage of net sales increased
50 basis points to 29.8% due to an increase in marketing spending and overhead costs as a percentage of net sales. Marketing spending as a percentage of net sales
increased 50 basis points due to investments in media, partially offset by the positive scale impacts of the net sales increase and savings in agency compensation,
production costs and advertising spending. Overhead costs as a percentage of net sales increased 20 basis points primarily due to inflation and other cost increases
and higher restructuring charges versus the base period, partially offset by the positive scale impacts of the net sales increase and productivity savings. Other net
operating costs as a percentage of net sales decreased 30 basis points due to a reduction in foreign exchange transactional charges. Productivity-driven cost savings
delivered 90 basis points of benefit to SG&A as a percentage of net sales.
Non-Operating Expenses and Income
Interest expense was $106 million for the quarter, a nominal increase versus the prior year period. Interest income was $11 million for the quarter, a $28 million
decrease versus the prior year period due to lower U.S. interest rates. Other non-operating income was $187 million, an increase of $81 million primarily due to an
unrealized gain on an equity investment that became publicly traded in the current period.
Income Taxes
For the three months ended March 31, 2021, the effective tax rate increased 70 basis points versus the prior year period to 16.2% due to:
• a 100 basis-point increase from lower excess tax benefits of share-based compensation (180 basis-point reduction in the current period versus 280 basis-point
reduction in the prior year period),
• a 150 basis-point increase related to the prior year tax benefit arising from transactions to simplify our legal entity structure, and
• a 10 basis-point increase from unfavorable impacts from the geographic mix of current year earnings.
These increases are partially offset by:
(1)
(2)
(1)
(2)
-- 19 of 53 --
• a 155 basis-point decrease from higher current period deductions for foreign-derived intangible income, and
• a 35 basis-point decrease from discrete impacts related to uncertain tax positions (65 basis-point favorable impact in the current year versus a 30 basis-point
favorable impact in the prior year period).
Net Earnings
Operating income increased $332 million, or 10%, to $3.8 billion for the quarter, due to the net sales increase and the increase in gross margin, partially offset by
the increase in SG&A as a percentage of sales, all of which are described above. Net earnings increased $292 million, or 10%, to $3.2 billion as the increases in
operating income and other non-operating income discussed above were partially offset by the increase in income taxes. Foreign exchange had a nominally positive
impact on net earnings for the quarter, including both transactional charges and translational impacts from converting earnings from foreign subsidiaries to U.S.
dollars. Net earnings attributable to Procter & Gamble increased $352 million, or 12%, to $3.3 billion for the quarter. Diluted net earnings per share increased 13%
to $1.26 versus the base period due to the increase in net earnings and a reduction in the weighted average number of shares outstanding. Diluted net EPS increased
8% versus the base period Core EPS which represents diluted net earnings per share excluding incremental restructuring charges in the base period related to our
productivity and cost savings plans.
RESULTS OF OPERATIONS – Nine Months Ended March 31, 2021
The following discussion provides a review of results for the nine months ended March 31, 2021 versus the nine months ended March 31, 2020.
Nine Months Ended March 31
Amounts in millions, except per share amounts 2021 2020 % Chg
Net sales $57,172 $53,252 7%
Operating income 14,446 12,225 18%
Net earnings 11,444 10,317 11%
Net earnings attributable to Procter & Gamble 11,400 10,227 11%
Diluted net earnings per common share 4.37 3.89 12%
Core net earnings per common share 4.53 3.96 14%
Nine Months Ended March 31
COMPARISONS AS A PERCENTAGE OF NET SALES 2021 2020 Basis Pt Chg
Gross margin 52.2% 50.6% 160
Selling, general & administrative expense 27.0% 27.6% (60)
Operating income 25.3% 23.0% 230
Earnings before income taxes 24.6% 23.2% 140
Net earnings 20.0% 19.4% 60
Net earnings attributable to Procter & Gamble 19.9% 19.2% 70
Net Sales
Net sales for the nine months ended March 31, 2021 increased 7% to $57.2 billion on a 4% increase in unit volume. Increased pricing had a 1% positive impact to
net sales. Mix had a 2% positive impact to net sales driven by the disproportionate growth of the North America region and the Home Care and Appliances
categories, all of which have higher than company-average selling prices. Foreign exchange had no net impact on net sales. Excluding the impact of acquisitions
and divestitures and foreign exchange, organic sales also increased 7% on a 4% increase in organic volume. Net sales increased double digits in Fabric & Home
Care, increased high single digits in Beauty and Health Care, increased mid-single digits in Grooming and increased low single digits in Baby, Feminine & Family
Care. On a regional basis, volume increased high single digits in North America and in Greater China driven by innovation and increased demand, particularly in
household cleaning and personal hygiene products due in part to the COVID-19 pandemic. Volume increased low single digits in Latin America and IMEA,
partially offset by a low single digits decrease in Asia Pacific. Volume was unchanged in Europe.
Net Sales Change Drivers 2021 vs. 2020 (Nine Months Ended March 31)
Volume with
Acquisitions &
Divestitures
Volume Excluding
Acquisitions &
Divestitures Foreign
Exchange Price Mix Other Net Sales
Growth
Beauty 4% 4% —% 2% 1% —% 7%
Grooming 3% 3% (1)% 2% 1% —% 5%
Health Care 4% 4% —% 1% 3% —% 8%
Fabric & Home Care 7% 7% —% 1% 3% —% 11%
Baby, Feminine & Family Care 1% 1% —% 1% 1% —% 3%
Total Company 4% 4% —% 1% 2% —% 7%
Net sales percentage changes are approximations based on quantitative formulas that are consistently applied.
Other includes the sales mix impact from acquisitions and divestitures and rounding impacts necessary to reconcile volume to net sales.
Operating Costs
Gross margin increased 160 basis points to 52.2% of net sales for the fiscal year to date period. Gross margin benefited from:
• 140 basis points of gross manufacturing cost savings projects (120 basis points net of product and packaging reinvestments),
• 60 basis points of help from higher pricing,
• 50 basis points of help due to lower restructuring costs versus the base period, and
• 20 basis points of lower commodity costs
These benefits were partially offset by a 50 basis-point decline from unfavorable foreign exchange and a 40 basis point decline from unfavorable mix (due to the
disproportionate growth of Home Care and Appliances categories which have lower than company-average margins, as well as mix within segments due to the
growth of lower margin product forms and large sizes in certain categories) and other impacts.
Total SG&A spending increased 5% to $15.4 billion primarily due to increases in both marketing spending and overhead costs. SG&A as a percentage of net sales
decreased 60 basis points to 27% primarily due to a reduction in overhead costs as a percentage of net sales. Marketing spending as a percentage of net sales was
(1)
(2)
(1)
(2)
-- 20 of 53 --
unchanged as the positive scale impacts of the net sales increase and savings in agency compensation, production costs and advertising spending, were offset by
reinvestments in media. Overhead costs as a percentage of net sales declined 40 basis points due to the positive scale impacts of the net sales increase and
productivity savings, partially offset by higher restructuring costs versus the base period, inflation and other cost increases. Other net operating costs as a
percentage of net sales decreased 20 basis points due to a reduction in foreign exchange transactional charges. Productivity-driven cost savings delivered 100 basis
points of benefit to SG&A as a percentage of net sales.
Non-Operating Expenses and Income
Interest expense was $385 million for the fiscal year to date, an increase of $77 million versus the prior year period due to higher average interest rates driven by a
higher proportion of fixed rate debt. Interest income was $30 million for the fiscal year to date, a $103 million decrease versus the prior year period due to lower
U.S. interest rates. Other non-operating expense was $40 million, a change of $363 million versus the prior year non-operating income of $323 million, primarily
due to current period charges of $512 million for early debt extinguishment ($427 million after tax), partially offset by an unrealized gain on an equity investment
that became publicly traded in the current period and an increase in net non-operating benefits on defined benefit retirement plans caused by annual updates to
actuarial assumptions.
Income Taxes
For the nine months ended March 31, 2021, the effective tax rate increased 200 basis points versus the prior year period to 18.6% due to:
• a 70 basis-point increase from unfavorable impacts from the geographic mix of current year earnings, caused primarily by disproportionately higher sales and
earnings in the U.S.,
• a 130 basis-point increase related to the prior year tax benefit arising from transactions to simplify our legal entity structure,
• a 10 basis-point increase from the impact of the early extinguishment of debt in the current year, and
• a 10 basis-point increase from lower excess tax benefits of share-based compensation (170 basis-point reduction in the current period versus 180 basis-point
reduction in the prior year period).
These increases are partially offset by:
• a 10 basis-point decrease from the higher current period deduction for foreign-derived intangible income, and
• a 10 basis-point decrease from discrete impacts related to uncertain tax positions (25 basis-point favorable impact in the current year versus a 15 basis-point
favorable impact in the prior year period).
Net Earnings
Operating income increased $2.2 billion, or 18%, to $14.4 billion for the nine months ended March 31, 2021, due to the net sales increase, the increase in gross
margin and the decrease in SG&A as a percentage of sales, all of which are described above. Net earnings increased $1.1 billion, or 11%, to $11.4 billion for the
fiscal year to date period primarily due to the increase in operating income, partially offset by the increase in other non-operating expense (driven by the early debt
extinguishment charge) and the increase in the effective tax rate. Foreign exchange had a negative impact of approximately $168 million on net earnings for the
fiscal year to date period, including both transactional charges and translational impacts from converting earnings from foreign subsidiaries to U.S. dollars. Net
earnings attributable to Procter & Gamble increased $1.2 billion, or 11%, to $11.4 billion for the fiscal year to date period. Diluted net earnings per share increased
12% to $4.37. Core net earnings per share increased 14% to $4.53. Core EPS represents diluted net earnings per share excluding current period charges for the
early extinguishment of debt and incremental restructuring charges in the base period related to our productivity and cost savings plans.
-- 21 of 53 --
BUSINESS SEGMENT DISCUSSION – Three and Nine Months Ended March 31, 2021
The following discussion provides a review of results by reportable business segment. Analysis of the results for the three- and nine month-periods ended
March 31, 2021 is provided based on a comparison to the same three- and nine-month periods ended March 31, 2020. The primary financial measures used to
evaluate segment performance are net sales and net earnings. The table below provides supplemental information on net sales, earnings before income taxes and net
earnings by reportable business segment for the three and nine months ended March 31, 2021 versus the comparable prior year period (dollar amounts in millions):
Three Months Ended March 31, 2021
Net Sales % Change
Versus Year Ago Earnings/(Loss) Before
Income Taxes % Change
Versus Year Ago Net Earnings % Change
Versus Year Ago
Beauty $ 3,316 9 % $ 721 30 % $ 577 32 %
Grooming 1,438 4 % 314 3 % 256 1 %
Health Care 2,356 4 % 484 (7) % 377 (8) %
Fabric & Home Care 6,275 8 % 1,348 6 % 1,027 7 %
Baby, Feminine & Family Care 4,604 — % 1,133 — % 871 1 %
Corporate 120 N/A (123) N/A 141 N/A
Total Company $ 18,109 5 % $ 3,877 11 % $ 3,249 10 %
Nine Months Ended March 31, 2021
Net Sales % Change
Versus Year Ago Earnings/(Loss) Before
Income Taxes % Change
Versus Year Ago Net Earnings % Change
Versus Year Ago
Beauty $ 10,907 7 % $ 3,145 16 % $ 2,508 16 %
Grooming 4,774 5 % 1,277 4 % 1,063 4 %
Health Care 7,573 8 % 1,993 11 % 1,557 13 %
Fabric & Home Care 19,417 11 % 4,689 21 % 3,626 23 %
Baby, Feminine & Family Care 14,185 3 % 3,803 14 % 2,924 15 %
Corporate 316 N/A (856) N/A (234) N/A
Total Company $ 57,172 7 % $ 14,051 14 % $ 11,444 11 %
Beauty
Three months ended March 31, 2021 compared with three months ended March 31, 2020
Beauty net sales increased 9% to $3.3 billion during the third fiscal quarter on a 2% increase in unit volume. Higher pricing increased net sales by 2%. Favorable
mix added 3% to net sales due to the disproportionate growth of the super premium SKII brand. Foreign exchange impacts increased net sales by 2%. Organic sales
increased 7%. Global market share of the Beauty segment decreased 0.5 points.
• Hair Care net sales increased high single digits due to a mid-single digit increase in volumes and devaluation-related price increases. Organic sales also
increased high single digits. The volume increase was driven by a more than 20% increase in Greater China (due to distribution growth and lower base period
volume caused by pandemic-related shutdowns) and high single digits increase in North America (due to innovation and lower base period volume caused by
pandemic-related supply constraints). Volume also increased double digits in IMEA and increased low single digits in Latin America due to innovation,
partially offset by double digit decline in Europe due to category declines and devaluation related price increases in certain markets. Global market share of the
Hair Care category was unchanged.
• Skin and Personal Care net sales increased double digits due to favorable mix impacts driven by the disproportionate growth of the super premium SKII brand,
increased pricing and favorable foreign exchange impacts, partially offset by a mid-single digit decrease in volumes. Organic sales increased high single digits.
Volume decreased mid-teens in IMEA, decreased double digits in Europe and Asia Pacific and decreased mid-single digits in North America, all primarily due
to pandemic-related skin care and deodorant category declines. This was partially offset by high single digits volume growth in Greater China driven by
increased consumption of personal care products due to the pandemic. Global market share of the Skin and Personal Care category decreased more than half a
point.
Net earnings increased 32% to $577 million due to the increase in net sales and a 300 basis-point increase in net earnings margin. The net earnings margin
increased due to a reduction in SG&A as a percentage of net sales and an increase in gross margin. The gross margin increase was driven by the positive impacts of
manufacturing cost savings and increased pricing,
-- 22 of 53 --
partially offset by increased commodity costs. The decrease in SG&A as a percentage of net sales was primarily due to the positive scale impacts of the net sales
increase.
Nine months ended March 31, 2021 compared with nine months ended March 31, 2020
Beauty fiscal year to date net sales increased 7% to $10.9 billion on a 4% increase in unit volume. Higher pricing increased net sales by 2%. Favorable mix added
1% to net sales due to the disproportionate growth of the super premium SKII brand. Foreign exchange had no net impact to net sales. Organic sales increased 6%.
Global market share of the Beauty segment decreased 0.7 points.
• Hair Care net sales increased mid-single digits due to a mid-single digit increase in volumes and increased pricing, partially offset by unfavorable foreign
exchange impacts. Organic sales increased high single digits. The volume increase was driven by a mid-teens increase in Greater China (due to market growth,
distribution growth and to a lesser extent the low base period due to pandemic-related shutdowns) and mid-single digits increases in North America, Latin
America and IMEA (due to innovation and increased demand following pandemic-related shutdowns), partially offset by a mid-single digits decrease in
Europe due to pandemic-related consumption declines. Global market share of the Hair Care category was unchanged.
• Skin and Personal Care net sales increased high single digits due to a low single digit increase in volumes, favorable mix due to the disproportionate growth of
the super premium SKII brand, increased pricing and favorable foreign exchange impacts. Organic sales increased mid-single digits. Volume grew double
digits in Greater China and grew low single digits in North America driven by increased consumption of personal care products due to the pandemic, partially
offset by double digits volume decrease in IMEA due to pandemic-related category declines. Global market share of the Skin and Personal Care category
decreased less than a point.
Net earnings increased 16% to $2.5 billion due to the increase in net sales and a 170 basis-point increase in net earnings margin. The net earnings margin increased
due to a reduction in SG&A as a percentage of net sales and an increase in gross margin. The gross margin increase was primarily driven by manufacturing cost
savings and increased selling prices, partially offset by the negative impacts of unfavorable mix due to the disproportionate growth of hair care which has lower
than segment-average gross margins. The decrease in SG&A as a percentage of net sales was primarily due to the positive scale impacts of the net sales increase.
Grooming
Three months ended March 31, 2021 compared with three months ended March 31, 2020
Grooming net sales increased 4% to $1.4 billion during the third fiscal quarter on unit volume that was unchanged. Pricing had a positive 2% impact on net sales.
Favorable mix had a positive 2% impact on net sales due to the disproportionate growth of Appliances category which has higher than segment-average selling
prices. Foreign exchange had no net impact to net sales. Organic sales also increased 4%. Global market share of the Grooming segment decreased 0.3 points.
• Shave Care net sales were unchanged as a low single digits volume decrease, unfavorable foreign exchange impacts and unfavorable mix impact (due to the
disproportionate growth of IMEA which has lower than category-average selling prices), were offset by devaluation-related price increases. Organic sales
were also unchanged. Volume decreased high single digits in Europe and Asia Pacific primarily due to pandemic-related consumption decline. This was
partially offset by double digit volume growth in IMEA (due to innovation), high single digit growth in Greater China (due to market growth) and low single
digit growth in North America (due to innovation and a lower base period due to pandemic-related distribution capacity limitations). Global market share of
the Shave Care category was unchanged.
• Appliances net sales increased more than 30% primarily due to a high teens volume increase, favorable foreign exchange impacts, increased pricing and
favorable mix due to the disproportionate growth of premium products. Organic sales increased more than 20%. Volume increased more than 20% in Europe
and increased mid-teens in North America due to innovation and increased consumption of at-home grooming and styling products driven by the pandemic.
Global market share of the Appliances category increased more than 3 points.
Net earnings increased 1% to $256 million due to the increase in net sales partially offset by a 60 basis-point decrease in net earnings margin. The net earnings
margin decreased due to a reduction in gross margin, partially offset by a reduction in SG&A as a percentage of net sales. The gross margin reduction was driven
by unfavorable foreign exchange impacts and the negative impact of unfavorable mix (due to the disproportionate growth of Appliances, which has lower than
segment-average margins), partially offset by manufacturing cost savings and increased selling prices. SG&A as a percentage of net sales decreased primarily due
to a reduction in overhead costs, driven by productivity savings and the positive scale impacts of the net sales increase, partially offset by an increase in marketing
spending.
Nine months ended March 31, 2021 compared with nine months ended March 31, 2020
Grooming fiscal year to date net sales increased 5% to $4.8 billion on a 3% increase in unit volume. Foreign exchange had a negative 1% impact on net sales.
Higher pricing increased net sales by 2%. Favorable mix had a 1% positive impact to net sales
-- 23 of 53 --
due to the disproportionate growth of the Appliances category, which has higher than segment-average selling prices. Organic sales also increased 5%. Global
market share of the Grooming segment decreased 0.8 points.
• Shave Care net sales decreased low single digits primarily due to unfavorable foreign exchange impacts and unfavorable mix (due to the disproportionate
growth of lower priced products in IMEA and Latin America), partially offset by a low single digit increase in volume and devaluation-related price increases.
Organic sales were unchanged. Volume increased mid-teens in IMEA, increased mid-single digits in Greater China and Latin America and increased low
single digits in North America due to product innovation and increased distribution in certain markets. This was partially offset by mid-single digit decreases
in Europe and Asia Pacific primarily due to pandemic-related consumption declines. Global market share of the Shave Care category was unchanged.
• Appliances net sales increased more than 30% primarily due to a more than 20% increase in volume, favorable foreign exchange impacts, increased pricing
and favorable mix due to the disproportionate growth of premium products. Organic sales increased around 30%. Volume increased in all regions led by a
more than 30% increase in Europe and North America and a double digit increase in Asia Pacific due to innovation and increased consumption of at-home
grooming and styling products driven by the pandemic. Global market share of the Appliances category increased more than two points.
Net earnings increased 4% to $1.1 billion due primarily to the increase in net sales. Net earnings margin was unchanged for the period as a reduction in SG&A as a
percentage of net sales was offset by a reduction in gross margin. Gross margin decreased due to unfavorable foreign exchange impacts and unfavorable mix
impacts (due to the disproportionate growth of the IMEA region and the Appliances category, both of which have lower than segment-average margins), partially
offset by manufacturing cost savings and increased selling prices. SG&A as a percentage of net sales decreased due to productivity savings and the positive scale
impacts of the net sales increase, partially offset by a favorable legal settlement in the base period.
Health Care
Three months ended March 31, 2021 compared with three months ended March 31, 2020
Health Care net sales increased 4% to $2.4 billion during the third fiscal quarter on unit volume that was unchanged. Favorable mix increased net sales by 3% due
to the disproportionate growth of premium power brush. Foreign exchange had a 1% positive impact on net sales. Pricing had no net impact to net sales. Organic
sales increased 3%. Global market share of the Health Care segment increased 2 points.
• Oral Care net sales increased double digits due to a low single digit increase in volume, favorable mix impacts due to the disproportionate growth of premium
power brush and favorable foreign exchange impacts. Organic sales increased high single digits. The volume increase was driven by a more than 20% growth
in IMEA (due to innovation), mid-teens growth in Greater China (due to innovation and a low base period volume due to pandemic-related lockdowns) and
low single digits growth in North America (due to innovation and increased marketing spending). These volume increases were partially offset by a high single
digits decline in Latin America (due to competitive activity and devaluation-related price increases) and a mid-single digits decline in Europe (due to
pandemic-related lockdowns in the current period and higher base period volume due to pandemic-related pantry loading). Global market share of the Oral
Care category increased more than half a point.
• Personal Health Care net sales decreased mid-single digits versus the prior year period due primarily to a mid-single digit decrease in volume. Favorable
geographic mix marginally improved net sales due to the disproportionate decline of certain markets in IMEA which have lower than category-average selling
prices. Organic sales also decreased mid-single digits. The volume decrease was driven by a high single digits decline in Europe and mid-single digits declines
in North America and IMEA primarily driven by a lower than average cough, cold and flu season in the current period and higher base period volume due to
pandemic-related pantry loading, partially offset by a mid-teens volume increase in Asia Pacific due to innovation and increased marketing spending. Global
market share of the Personal Health Care category increased more than a point.
Net earnings decreased 8% to $377 million due to a 200 basis-point decrease in net earnings margin, partially offset by the increase in net sales. Net earnings
margin decreased due to a decrease in gross margin and an increase in SG&A as a percentage of net sales. The decrease in gross margin was driven by unfavorable
mix impacts (due to the disproportionate growth of the Oral care category, which has lower than segment-average margins and the decline in higher-margin
respiratory products), and unfavorable foreign exchange impacts, partially offset by manufacturing cost savings. SG&A as a percentage of net sales increased
primarily due to an increase in marketing spending.
Nine months ended March 31, 2021 compared with nine months ended March 31, 2020
Health Care fiscal year to date net sales increased 8% to $7.6 billion on a 4% increase in unit volume. Favorable mix increased net sales by 3% due to the
disproportionate growth of the North America region and premium power brush and paste products, both of which have higher than segment-average selling prices.
Increased pricing had a positive 1% impact to net sales. Foreign
-- 24 of 53 --
exchange had no net impact to net sales. Organic sales also increased 8%. Global market share of the Health Care segment increased 1.7 points.
• Oral Care net sales increased double digits due to a mid-single digit increase in volume and favorable mix impacts from the disproportionate growth of
premium power brush and paste products. Organic sales also increased double digits. The volume increase was driven by mid-teens growth in IMEA, double
digit growth in Greater China, mid-single digit growth in North America and low single digits growth in Europe driven by innovation and increased marketing
spending. Global market share of the Oral Care category increased a point.
• Personal Health Care net sales increased low single digits versus the prior year period due to a low single digit increase in volume and increased pricing,
partially offset by unfavorable foreign exchange impacts. Organic sales also increased low single digits. The volume increase was driven by double digits
growth in Asia Pacific, high single digits growth in Latin America, mid-single digits growth in North America and low single digits growth in IMEA, driven
by innovation, increased consumption of certain health care products and increased marketing spending. Global market share of the Personal Health Care
category increased more than a point.
Net earnings increased 13% to $1.6 billion due to the increase in net sales and a 90 basis-point increase in net earnings margin. Net earnings margin increased
primarily due to a decrease in SG&A as a percentage of net sales and a gain on a minor brand divestiture in the current period, partially offset by a decrease in
gross margin. The decrease in gross margin was driven by unfavorable mix impacts (due to the disproportionate growth of the Oral Care category, which has lower
than segment-average margins and the decline of higher-margin respiratory products), and unfavorable foreign exchange impacts, partially offset by manufacturing
cost savings. SG&A as a percentage of net sales decreased primarily due to the positive scale benefits of the net sales increase, productivity savings and a reduction
in other operating expenses due to costs related to the Merck OTC consumer healthcare acquisition in the base period, partially offset by increased marketing
spending.
Fabric & Home Care
Three months ended March 31, 2021 compared with three months ended March 31, 2020
Fabric & Home Care net sales increased 8% to $6.3 billion during the third fiscal quarter on a 3% increase in unit volume. Positive mix impacts increased net sales
by 2% due to the disproportionate growth of the North America region and the Home Care category, which have higher than segment-average prices. Higher
pricing increased net sales by 2%. Foreign exchange had a 1% positive impact to net sales. Organic sales increased 7%. Global market share of the Fabric & Home
Care segment increased 0.7 points.
• Fabric Care net sales increased mid-single digits due to a low single digit increase in volume, devaluation-related price increases, favorable foreign exchange
impacts and positive mix impact due to the disproportionate growth of premium products and the North America region, both of which have higher than
category-average selling prices. Organic sales increased low single digits. Increased volume was driven by more than 20% growth in Greater China (due to
innovation and a lower base period due to pandemic-related lockdowns) and mid-single digits growth in North America (due to innovation and increased
marketing spending), partially offset by a mid-single digits decline in Europe due to pandemic-related market contraction. Global market share of the Fabric
Care category increased more than a point.
• Home Care net sales increased high teens, primarily due to a double digit increase in volume, increased pricing, a positive mix impact due to the
disproportionate growth of premium products and the North America region, both of which have higher than category-average selling prices and favorable
foreign exchange impact. Organic sales also increased high teens. The volume increase was primarily driven by mid-teens growth in North America and high
single digits growth in Europe due to consumption increases related to the COVID-19 pandemic, product innovation and increased marketing spending. Global
market share of the Home Care category increased more than half a point.
Net earnings increased 7% to $1.0 billion primarily due to the increase in net sales. Net earnings margin was unchanged as an increase in gross margin was offset
by an increase in SG&A as a percentage of sales. The gross margin increase was driven by increased selling prices and manufacturing cost savings, partially offset
by unfavorable mix impacts due to the disproportionate growth of products with lower than segment-average margins, unfavorable foreign exchange impacts and
an increase in commodity costs. SG&A as a percentage of net sales increased primarily due to an increase in marketing spending, partially offset by the positive
scale benefits of the net sales increase.
Nine months ended March 31, 2021 compared with nine months ended March 31, 2020
Fabric & Home Care fiscal year to date net sales increased 11% to $19.4 billion on a 7% increase in unit volume. Positive mix impacts increased net sales by 3%
due to the disproportionate growth of the North America region and the Home Care category, both of which have higher than segment-average prices. Higher
pricing increased net sales by 1%. Foreign exchange had no net impact to net sales. Organic sales also increased 11%. Global market share of the Fabric & Home
Care segment increased 0.9 points.
-- 25 of 53 --
• Fabric Care net sales increased high single digits due to a mid-single digit increase in volume, positive mix impact due to the disproportionate growth of
premium products and the North America region and increased pricing. Organic sales increased mid-single digits. Increased volume was driven by double
digit growth in North America and Greater China due to product innovation, incremental marketing spending and consumption increases related to the
COVID-19 pandemic. These volume increases were partially offset by a low single digits decline in Europe and Asia Pacific due to market contraction and
competitive activities. Global market share of the Fabric Care category increased more than a point.
• Home Care net sales increased more than 20% primarily due to a volume increase of around 20%, positive mix impact due to the disproportionate growth of
premium products and the North America region, both of which have higher than segment-average prices, and increased pricing. Organic sales also increased
more than 20%. Volume increased in all regions led by more than 20% growth in North America, high teens growth in Latin America, mid-teens growth in
Europe, and high single digits growth in Asia Pacific (all due to consumption increases related to the COVID-19 pandemic), product innovation and
incremental marketing spending. Global market share of the Home Care category increased more than half a point.
Net earnings increased 23% to $3.6 billion due to the increase in net sales and a 170 basis-point increase in net earnings margin. The net earnings margin increase
was due to an increase in gross margin and a marginal decrease in SG&A as a percentage of sales. The gross margin increase was driven by manufacturing cost
savings, increased selling prices and a reduction in commodity costs, partially offset by unfavorable foreign exchange impacts and unfavorable mix due to the
disproportionate growth of products with lower than segment-average margins. SG&A as a percentage of net sales decreased primarily due to the positive scale
benefits of the net sales increase, partially offset by an increase in marketing spending.
Baby, Feminine & Family Care
Three months ended March 31, 2021 compared with three months ended March 31, 2020
Baby, Feminine & Family Care net sales were unchanged at $4.6 billion during the third fiscal quarter on a 4% decrease in unit volume. Higher pricing increased
net sales by 2%. Favorable mix had a 1% positive impact to net sales due to the disproportionate growth of premium products, including diaper pants and adult
incontinence. Foreign exchange had a 1% positive impact to net sales. Organic sales decreased 1%. Global market share of the Baby, Feminine & Family Care
segment decreased 0.6 points.
• Net sales in Baby Care decreased mid-single digits due to a high single digit decrease in volume, partially offset by favorable foreign exchange impact and
positive mix impact due to the relatively lower decline of the North America region and the growth of premium products. Organic sales also decreased mid-
single digits. Volume decreased mid-teens in Asia Pacific (due to competitive activity and category contraction in certain markets), decreased double digits in
Greater China (due to competitive activity) and Europe (due to reduction in retailer inventories, competitive activity in certain markets and higher base period
volume due to pandemic-related pantry loading), and decreased mid-single digits in North America (primarily due to higher base period volume due to
pandemic-related pantry loading). Global market share of the Baby Care category decreased nearly half a point.
• Feminine Care net sales were unchanged as a mid-single digit volume decline was offset by a positive mix impact driven by the growth of the North America
region and premium products and favorable foreign exchange impact. Organic sales decreased low single digits. Volume decreased high-teens in Europe (due
to pandemic-related market declines in the current period and higher base period volume due to pandemic-related pantry loading) and decreased mid-single
digits in Latin America (due to pandemic-related consumption declines and competitive activity). This was partially offset by a mid-single digits volume
increase in Greater China and a low single digits increase in North America and IMEA, primarily due to innovation. Global market share of the Feminine Care
category increased more than half a point.
• Net sales in Family Care, which is predominantly a North American business, increased mid-single digits primarily due to increased pricing (driven by lower
consumer promotions). Volume was unchanged. Organic sales also increased mid-single digits. North America share of the Family Care category decreased
more than two points.
Net earnings increased 1% to $871 million primarily due to a 20 basis-point increase in net earnings margin. Net earnings margin increased primarily due to an
increase in gross margin, offset by an increase in SG&A as a percentage of net sales. Gross margin increased primarily due to higher selling prices, partially offset
by unfavorable foreign exchange impacts and an increase in commodity costs. SG&A as a percentage of net sales increased primarily due to an increase in
overhead costs.
Nine months ended March 31, 2021 compared with nine months ended March 31, 2020
Baby, Feminine & Family Care fiscal year to date net sales increased 3% to $14.2 billion on a 1% increase in unit volume. Higher pricing increased net sales by
1%. Favorable mix impact increased net sales by 1% due to the disproportionate growth of the North America region. Foreign exchange had no net impact to net
sales. Organic sales also increased 3%. Global market share of the Baby, Feminine & Family Care segment decreased 0.4 points.
• Net sales in Baby Care decreased low single digits due to a mid-single digit decrease in volume, partially offset by devaluation-related price increases and
positive mix impact due to the growth of the North America region and premium
-- 26 of 53 --
products. Organic sales also decreased low single digits. Volume decreased double digits in Greater China (due to competitive activity and consumer pantry
destocking), decreased high single digits in Latin America (due to market contraction), IMEA (due to pandemic-related retailer inventory reductions and
market contraction), and Asia Pacific (due primarily to market contractions and competitive activity) and decreased mid-single digits in Europe (due to market
contractions and competitive activity in certain markets). These volume decreases were partially offset by low single digits volume growth in North America
due to consumption increase in certain products and innovation. Global market share of the Baby Care category decreased more than half a point.
• Feminine Care net sales increased mid-single digits due to increased pricing and positive mix impact of the growth of the North America region and premium
products. This was partially offset by a low single digit decrease in global volume. Organic sales also increased mid-single digits. Volume decreased high
single digits in Europe (due to pandemic-related consumption declines) and decreased mid-single digits in Latin America (due to competitive activity and
pandemic-related consumption declines). Volume increased mid-single digits in North America (due to innovation) and in IMEA (primarily due to market
growth and innovation). Global market share of the Feminine Care category increased less than a point.
• Net sales in Family Care, which is predominantly a North American business, increased double digits driven by a high single digit increase in volumes and
increased pricing driven by lower consumer promotions, partially offset by unfavorable mix impact due to the disproportionate growth of larger pack sizes.
Organic sales also increased double digits. The volume increase was driven by a pandemic-related consumption increase and pantry loading, and to a lesser
extent, retailer inventory restocking. North America share of the Family Care category decreased more than a point.
Net earnings increased 15% to $2.9 billion due to the increase in net sales and a 200 basis-point increase in net earnings margin. Net earnings margin increased
primarily due to an increase in gross margin, and to a lesser extent, a decrease in SG&A as a percentage of net sales. Gross margin increased due to manufacturing
cost savings, increased selling prices and a reduction in commodity costs, partially offset by unfavorable foreign exchange impacts. SG&A as a percentage of net
sales decreased primarily due to the positive scale benefits of the net sales increase.
Corporate
Corporate includes certain operating and non-operating activities not allocated to specific business segments. These include: the incidental businesses managed at
the corporate level; financing and investing activities; certain employee benefit costs; other general corporate items; the gains and losses related to certain divested
brands and categories; and certain restructuring-type activities to maintain a competitive cost structure, including manufacturing and workforce optimization.
Corporate also includes reconciling items to adjust the accounting policies used in the reportable segments to U.S. GAAP. The most significant reconciling item
relates to income taxes, to adjust from blended statutory rates that are reflected in the reportable segments to the overall Company effective tax rate.
Corporate net sales improved by $4 million to $120 million for the quarter ended March 31, 2021 and increased $10 million to $316 million for the fiscal year to
date. Corporate net earnings improved by $98 million in the quarter due to lower restructuring charges versus the base period and the current period unrealized gain
on an equity investment that became publicly traded in the quarter, partially offset by a higher current period tax rate all of which have been described above.
Corporate net earnings decreased $473 million for the fiscal year to date period, primarily due to the $427 million ($512 million before tax) current period charge
for early debt extinguishment, higher interest expense, lower interest income, and the higher current year tax rate, partially offset by lower restructuring charges
versus the base period and the current period unrealized gain from an equity investment, all of which have been described above.
Restructuring Program to deliver Productivity and Cost Savings
In 2012, the Company initiated a productivity and cost savings plan to reduce costs and better leverage scale in the areas of supply chain, research and
development, marketing and overheads. The plan was designed to accelerate cost reductions by streamlining management decision making, manufacturing and
other work processes to fund the Company's growth strategy. In 2017, the Company communicated specific elements of an additional multi-year productivity and
cost savings program. As part of this plan, which was largely completed by the end of fiscal 2020, the Company incurred $1.5 billion in total before-tax
restructuring costs across fiscal 2019 and fiscal 2020.
In fiscal 2021 and onwards, the Company expects to incur restructuring costs within the range of our historical ongoing level of $250 to $500 million before tax. In
addition to our restructuring programs, we have additional ongoing savings efforts in our supply chain, marketing and overhead areas that have and are expected to
continue to yield additional benefits to our operating margins.
Refer to Note 9 in the Notes to the Consolidated Financial Statements for more details on the restructuring program.
LIQUIDITY & CAPITAL RESOURCES
Operating Activities
We generated $14.3 billion of cash from operating activities fiscal year to date, an increase of $1.7 billion versus the prior year period. Net earnings, adjusted for
non-cash items (depreciation and amortization, loss on extinguishment of debt, share-based compensation expense, deferred income taxes and gain on sale of
assets), generated $14.2 billion of operating cash flow. Working capital and other impacts generated $53 million of cash in the period. Accounts receivable
increased, using $604 million of cash, primarily due to sales growth. Days sales outstanding also increased about two days driven by higher relative amount of
sales towards the end of the quarter. Inventory increased, consuming $399 million of cash primarily due to business growth, increased safety stock levels during the
COVID-19 pandemic and commodity cost increases. Accounts payable, accrued and other liabilities increased, generating $1.0 billion of cash. About half of this
increase was driven by extended payment terms to suppliers. The remaining increase is due to higher marketing spending and to support the increase in inventory.
These increases were partially offset by the payment of prior fiscal year-end incentive compensation and other salary-related accruals.
Investing Activities
Investing activities used $2.0 billion of cash fiscal year to date primarily due to capital expenditures.
Financing Activities
Financing activities used $18.4 billion of cash fiscal year to date. We used $8.0 billion for treasury stock purchases and $6.1 billion for dividends. We used $5.8
billion for net debt reductions, including $512 million for early debt extinguishment costs related to the early retirement of $2.3 billion of debt. The exercise of
stock options and other financing activities generated $1.5 billion of cash.
As of March 31, 2021, our current liabilities exceeded current assets by $9.4 billion. We have short- and long-term debt to meet our financing needs. We anticipate
being able to support our short-term liquidity and operating needs largely through cash generated from operations. We have strong short- and long-term debt
ratings that have enabled and should continue to enable us to refinance our debt as it becomes due at favorable rates in commercial paper and bond markets. In
addition, we have agreements with a diverse group of financial institutions that, if needed, should provide sufficient credit funding to meet short-term financing
requirements.
-- 27 of 53 --
RECONCILIATION OF MEASURES NOT DEFINED BY U.S. GAAP
In accordance with the SEC's Regulation S-K Item 10(e), the following provides definitions of the non-GAAP measures and the reconciliation to the most closely
related GAAP measures. We believe that these measures provide useful perspective on underlying business results and trends (i.e., trends excluding non-recurring
or unusual items) and provide a supplemental measure of year-on-year results. The non-GAAP measures described below are used by management in making
operating decisions, allocating financial resources and for business strategy purposes. These measures may be useful to investors as they provide supplemental
information about business performance and provide investors a view of our business results through the eyes of management. These measures are also used to
evaluate senior management and are a factor in determining their at-risk compensation. These non-GAAP measures are not intended to be considered by the user in
place of the related GAAP measures, but rather as supplemental information to our business results. These non-GAAP measures may not be the same as similar
measures used by other companies due to possible differences in method and in the items or events being adjusted.
Organic sales growth: Organic sales growth is a non-GAAP measure of sales growth excluding the impacts of acquisitions and divestitures and foreign exchange
from year-over-year comparisons. We believe this measure provides investors with a supplemental understanding of underlying sales trends by providing sales
growth on a consistent basis. This measure is used in assessing achievement of management goals for at-risk compensation.
Adjusted free cash flow: Adjusted free cash flow is defined as operating cash flow less capital spending and excluding payments for the transitional tax resulting
from the U.S. Tax Act (the company incurred a transitional tax liability of approximately $3.8 billion in fiscal 2018 from the U.S. Tax Act of 2017 which is
payable over a period of 8 years). Adjusted free cash flow represents the cash that the Company is able to generate after taking into account planned maintenance
and asset expansion. Management views adjusted free cash flow as an important measure because it is one factor used in determining the amount of cash available
for dividends, share repurchases, acquisitions and other discretionary investments.
Adjusted free cash flow productivity: Adjusted free cash flow productivity is defined as the ratio of adjusted free cash flow to net earnings excluding the charges
for early debt extinguishment (which are not considered part of our ongoing operations). Management views adjusted free cash flow productivity as a useful
measure to help investors understand P&G’s ability to generate cash. Adjusted free cash flow productivity is used by management in making operating decisions,
allocating financial resources and for budget planning purposes. This measure is also used in assessing the achievement of management goals for at-risk
compensation. The Company's long-term target is to generate annual adjusted free cash flow productivity at or above 90 percent.
Core EPS: Core earnings per share, or Core EPS, is a measure of the Company's diluted net earnings per share adjusted as indicated. Management views this non-
GAAP measure as a useful supplemental measure of Company performance over time. This measure is also used when evaluating senior management in
determining their at-risk compensation.
The Core earnings measures included in the following reconciliation tables refer to the equivalent GAAP measures adjusted as applicable for the following items:
Incremental Restructuring: The Company has historically had an ongoing level of restructuring activities. Such activities have resulted in ongoing annual
restructuring-related charges of approximately $250 - $500 million before tax. Beginning in 2012, the Company has had a strategic productivity and cost savings
initiative that resulted in incremental restructuring charges. The adjustment to Core earnings includes only the restructuring costs above what we believe are the
normal recurring level of restructuring costs. In fiscal 2021 and onwards, the Company expects to incur restructuring costs within our historical ongoing level
noted above.
Early debt extinguishment charges: In the three months ended December 31, 2020, the Company recorded after tax charges of $427 million ($512 million before
tax), due to early extinguishment of certain long-term debt. These charges represent the difference between the reacquisition price and the par value of the debt
extinguished.
We do not view the above items to be part of our sustainable results and their exclusion from Core earnings measures provides a more comparable measure of year-
over-year results. These items are also excluded when evaluating senior management in determining their at-risk compensation.
Organic sales growth:
Three Months Ended March 31, 2021 Net Sales Growth Foreign Exchange Impact Acquisition & Divestiture
Impact/Other Organic Sales Growth
Beauty 9% (2)% —% 7%
Grooming 4% —% —% 4%
Health Care 4% (1)% —% 3%
Fabric & Home Care 8% (1)% —% 7%
Baby, Feminine & Family Care —% (1)% —% (1)%
Total Company 5% (1)% —% 4%
Acquisitions/Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net
sales to organic sales.
Nine Months Ended March 31, 2021 Net Sales Growth Foreign Exchange Acquisition & Divestiture
Impact/Other Organic Sales Growth
Beauty 7% —% (1)% 6%
Grooming 5% 1% (1)% 5%
Health Care 8% —% —% 8%
Fabric & Home Care 11% —% —% 11%
Baby, Feminine & Family Care 3% —% —% 3%
Total Company 7% —% —% 7%
Acquisitions/Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net
sales to organic sales.
Adjusted free cash flow (dollar amounts in millions):
Nine Months Ended March 31, 2021
Operating Cash Flow Capital Spending U.S. Tax Act Payments Adjusted Free Cash Flow
$14,250 $(2,073) $225 $12,402
Adjusted free cash flow productivity (dollar amounts in millions):
Nine Months Ended March 31, 2021
(1)
(1)
(1)
(1)
-- 28 of 53 --
Adjusted Free Cash Flow Net Earnings Early Debt Extinguishment Charges
Net Earnings Excluding
Adjustments
Adjusted Free Cash Flow
Productivity
$12,402 $11,444 $427 $11,871 104%
-- 29 of 53 --
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
(Amounts in Millions Except Per Share Amounts)
Reconciliation of Non-GAAP Measures
Three Months
Ended March 31,
2021 Three Months Ended March 31, 2020
AS REPORTED
(GAAP) AS REPORTED
(GAAP) INCREMENTAL
RESTRUCTURING NON-GAAP
(CORE)
NET EARNINGS ATTRIBUTABLE TO P&G 3,269 2,917 141 3,058
Core EPS
DILUTED NET EARNINGS PER COMMON SHARE $ 1.26 $ 1.12 $ 0.05 $ 1.17
Diluted net earnings per share are calculated on Net earnings attributable to Procter & Gamble.
CHANGE IN CURRENT YEAR REPORTED (GAAP) MEASURES VERSUS PRIOR
YEAR NON-GAAP (CORE) MEASURES
NET EARNINGS ATTRIBUTABLE TO P&G 7 %
EPS 8 %
Change versus year ago is calculated based on As Reported (GAAP) values for the three months ended March 31, 2021 versus the Non-GAAP (Core) values for the three
months ended March 31, 2020.
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
(Amounts in Millions Except Per Share Amounts)
Reconciliation of Non-GAAP Measures
Nine Months Ended March 31, 2021 Nine Months Ended March 31, 2020
AS REPORTED
(GAAP)
EARLY DEBT
EXTINGUISHMENT
NON-GAAP
(CORE)
AS REPORTED
(GAAP)
INCREMENTAL
RESTRUCTURING
NON-GAAP
(CORE)
NET EARNINGS ATTRIBUTABLE TO P&G 11,400 427 11,827 10,227 189 10,416
Core EPS
DILUTED NET EARNINGS PER COMMON SHARE $ 4.37 $ 0.16 $ 4.53 $ 3.89 $ 0.07 $ 3.96
Diluted net earnings per share are calculated on Net earnings attributable to Procter & Gamble.
CHANGE VERSUS YEAR AGO
CORE NET EARNINGS ATTRIBUTABLE TO P&G 14 %
CORE EPS 14 %
(1)
(1)
(1)
(1)
(1)
(1)
-- 30 of 53 --
Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in the Company’s exposure to market risk since June 30, 2020. Additional information can be found in Note 7 - Risk
Management Activities and Fair Value Measurements of the Consolidated Financial Statements.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The Company’s Chairman of the Board, President and Chief Executive Officer, David S. Taylor, and the Company’s Chief Financial Officer, Andre Schulten,
performed an evaluation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934
(“Exchange Act”)) as of the end of the period covered by this report. Messrs. Taylor and Schulten have concluded that the Company’s disclosure controls and
procedures were effective to ensure that information required to be disclosed in reports we file or submit under the Exchange Act is (1) recorded, processed,
summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and (2) accumulated and communicated to our
management, including Messrs. Taylor and Schulten, to allow their timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the Company’s fiscal quarter ended March 31, 2021 that have materially
affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
The Company is subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including
antitrust and trade regulation, product liability, advertising, contracts, environmental issues, patent and trademark matters, labor and employment matters, and tax.
In addition, SEC regulations require that we disclose certain environmental proceedings arising under Federal, State, or local law when a governmental authority is
a party and such proceeding involves potential monetary sanctions that the Company reasonably believes will exceed a certain threshold ($1 million or more).
There are no relevant matters to disclose under this Item for this period.
Item 1A. Risk Factors
For information on risk factors, please refer to "Risk Factors" in Part I, Item 1A of the Company's Form 10-K/A for the year ended June 30, 2020.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
ISSUER PURCHASES OF EQUITY SECURITIES
Period Total Number of Shares
Purchased Average Price Paid per
Share
Total Number of Shares Purchased as
Part of Publicly Announced Plans or
Programs
Approximate Dollar Value of Shares That May
Yet Be Purchased Under Our Share
Repurchase Program
1/01/2021 - 1/31/2021 5,172,115 $135.34 5,172,115
2/01/2021 - 2/28/2021 10,121,457 $128.44 10,121,457
3/01/2021 - 3/31/2021 7,791,329 $128.35 7,791,329
Total 23,084,901 $129.96 23,084,901
All transactions are reported on a trade date basis and were made in the open market with large financial institutions. This table excludes shares withheld from
employees to satisfy minimum tax withholding requirements on option exercises and other equity-based transactions. The Company administers cashless
exercises through an independent third party and does not repurchase stock in connection with cashless exercises.
Average price paid per share for open market transactions excludes commission.
On April 20, 2021, the Company stated that in fiscal year 2021 the Company expects to reduce outstanding shares through direct share repurchases at a value
of approximately $11 billion, notwithstanding any purchases under the Company's compensation and benefit plans. Purchases may be made in the open market
and/or private transactions and purchases may be increased, decreased or discontinued at any time without prior notice. The share repurchases are authorized
pursuant to a resolution issued by the Company's Board of Directors and are expected to be financed by a combination of operating cash flows and issuance of
long-term and short-term debt.
(1) (2) (3)
(3)
(3)
(3)
(1)
(2)
(3)
-- 31 of 53 --
Item 6. Exhibits
3-1 Amended Articles of Incorporation (as amended by shareholders at the annual meeting on October 11, 2011 and consolidated by the
Board of Directors on April 8, 2016) (Incorporated by reference to Exhibit (3-1) of the Company's Form 10-K for the year ended June 30,
2016).
3-2 Regulations (as approved by the Board of Directors on April 8, 2016, pursuant to authority granted by shareholders at the annual meeting
on October 13, 2009) (Incorporated by reference to Exhibit (3-2) of the Company's Form 10-K for the year ended June 30, 2016).
10-1 Company’s Form of Separation Letter & Release* +
10-2 Company’s Form of Separation Agreement & Release* +
31.1 Rule 13a-14(a)/15d-14(a) Certification – Chief Executive Officer +
31.2 Rule 13a-14(a)/15d-14(a) Certification – Chief Financial Officer +
32.1 Section 1350 Certifications – Chief Executive Officer +
32.2 Section 1350 Certifications – Chief Financial Officer +
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
* Compensatory plan or arrangement
+ Filed herewith
Pursuant to Rule 406T of Regulation S-T, this information is furnished and not filed for purposes of Sections 11 or 12 of the Securities Act of 1933 and
Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.
(1)
(1)
(1)
(1)
(1)
(1)
-- 32 of 53 --
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned
thereunto duly authorized.
THE PROCTER & GAMBLE COMPANY
April 20, 2021 /s/ MICHAEL G. HOMAN
Date (Michael G. Homan)
Senior Vice President - Chief Accounting Officer
-- 33 of 53 --
EXHIBIT INDEX
Exhibit
3-1 Amended Articles of Incorporation (as amended by shareholders at the annual meeting on October 11, 2011 and consolidated by the
Board of Directors on April 8, 2016) (Incorporated by reference to Exhibit (3-1) of the Company's Form 10-K for the year ended June
30, 2016)
3-2 Regulations (as approved by the Board of Directors on April 8, 2016, pursuant to authority granted by shareholders at the annual meeting
on October 13, 2009) (Incorporated by reference to Exhibit (3-2) of the Company's Form 10-K for the year ended June 30, 2016)
10-1 Company’s Form of Separation Letter & Release +
10-2 Company’s Form of Separation Agreement & Release +
31.1 Rule 13a-14(a)/Rule 13a-14(a)/15d-14(a) Certification – Chief Executive Officer +
31.2 Rule 13a-14(a)/15d-14(a) Certification – Chief Financial Officer +
32.1 Section 1350 Certifications – Chief Executive Officer +
32.2 Section 1350 Certifications – Chief Financial Officer +
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
+ Filed herewith
Pursuant to Rule 406T of Regulation S-T, this information is furnished and not filed for purposes of Sections 11 or 12 of the Securities Act of 1933 and
Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.
(1)
(1)
(1)
(1)
(1)
(1)
-- 34 of 53 --
Exhibit (10-1)
Company’s Form of Separation Letter & Release
-- 35 of 53 --
[ON P&G LETTERHEAD]
[INSERT DATE]
[INSERT EMPLOYEE NAME]
[INSERT EMPLOYEE ADDRESS]
[INSERT EMPLOYEE ADDRESS]
RE: Separation Letter & Release
Dear [INSERT EMPLOYEE NAME]:
[INSERT PROPER LEGAL ENTITY] (“P&G”) is willing to assist you following your employment separation from P&G in
exchange for your agreement and compliance with the terms set forth below.
Employment Separation Date: Your last day of employment with P&G will be [INSERT DATE], which will be your
“Employment Separation Date” for purposes of this letter. You understand and agree that if P&G
determines that you engaged in misconduct during your employment, or if you fail to perform your
work and responsibilities in a satisfactory manner up to and including your Employment Separation
Date, P&G may terminate your employment immediately and will not provide, nor be obligated to
provide, the payment(s) and other benefits described in this letter.
Vacation: You will receive payment for your accrued but unused vacation as of your Employment Separation
Date, which sum will be paid to you in accordance with P&G policy and applicable laws. You will
not accrue any additional vacation following your Employment Separation Date.
STAR Award
(use this paragraph only if the
employee is eligible for STAR
awards)
As of your Employment Separation Date, if you were otherwise eligible for a STAR award and you
worked at least 28 days (4 calendar weeks) during the fiscal year, you will receive a pro-rated
STAR award for the fiscal year. Your STAR award will be pro-rated by dividing the number of
calendar days during the fiscal year from July 1 through your Employment Separation Date by 365.
Your STAR award will be paid in cash in the September (but no later than September 15th)
immediately following the end of the fiscal year in which your employment terminates with P&G.
Separation Payment (use this
paragraph only if a separation
payment will be provided):
P&G will, within thirty (30) calendar days after your Employment Separation Date, provide you
with a separation payment in the amount of $[INSERT AMOUNT] (“Separation Payment”)
(representing [INSERT #] weeks of pay at your current salary), less applicable state and federal
withholdings and deductions, which sum will be paid in one lump sum payment. The Separation
Payment will be the only assistance P&G provides upon your separation. Other resources may be
available to you as a participant in general compensation and benefit plans, which it will be your
responsibility to identify and make any necessary arrangements upon separation.
Amounts you owe to P&G as of your Employment Separation Date, including, but not limited to,
wage and/or benefit overpayments and unpaid loans, will also be deducted from the Separation
Payment.
Unemployment Compensation
Benefits (use this paragraph
only if a separation payment is
being provided):
Your Separation Payment will be allocated to the [INSERT #] week period following your
Employment Separation Date.
-- 36 of 53 --
Special Retirement (“Rule of
70”) (use this paragraph
only if the Company has
decided to give access to
special retirement upon
separation)
P&G will agree to allow the “Rule of 70” to apply to you, but only for purposes of eligibility for
retiree health care benefits under the Procter & Gamble Retiree Welfare Benefits Plan. The Rule of 70
is a special eligibility rule for retiree health care coverage (including medical, dental, and prescription
drug benefits) under the Procter & Gamble Retiree Welfare Benefits Plan that only applies in specific
circumstances. The Rule of 70 will apply to you with respect to health care coverage under the Procter
& Gamble Retiree Welfare Benefits Plan as long as that Plan continues to exist and as long as the Rule
of 70 continues as an eligibility rule for coverage under that Plan.
For purposes of this paragraph only, the parties agree that your employment with P&G ended on
[EMPLOYMENT SEPARATION DATE], and that you were not terminated for cause. The parties
also agree that at the time your employment with the Company ended, you were [##] years old and had
[##] years of service with the Company, making your full years of age plus full years of service
[TOTAL], which is greater than 70.
To avoid confusion, other than establishing that the Rule of 70 applies to you for purposes of retiree
health care coverage under the Procter & Gamble Welfare Benefits Plan, you are subject to the same
terms and conditions of the Procter & Gamble Welfare Benefits Plan, including but not limited to (1)
coverage does not begin until you enrolls in the Plan, and once enrolled coverage is only prospective,
(2) the monthly premiums required for coverage under the Plan must be paid on time to avoid
coverage from terminating, (3) you will become ineligible for coverage under the Plan while you are
employed by a direct competitor of P&G (as determined by P&G’s Chief Human Resources Officer)
in an officer and/or director capacity (if you were at Band 5 or below at the time your employment
with the Company ended) or in any capacity (if you were at Band 6 or above at the time your
employment with the Company ended), and (4) the Company’s reservation of amendment and
termination rights with respect to the Plan.
Retention of Vested &
Unvested Equity Awards (use
this paragraph only if the
Company has decided to
allow the person to retain
his/her equity and the proper
approvals have been
obtained)
Your separation will be treated as a Special Separation for purposes of any outstanding equity awards
granted under the Procter & Gamble 2009 Stock and Incentive Compensation Plan, the Procter &
Gamble 2001 Stock and Incentive Compensation Plan, the Procter & Gamble 1992 Stock Plan, or the
Gillette Company 2004 Long-Term Incentive Plan and, as a result, you will retain the awards subject
to the original terms and conditions of the awards. You will also retain awards granted under the
Procter & Gamble 2014 Stock & Incentive Compensation Plan and the Procter & Gamble 2019 Stock
& Incentive Compensation Plan subject to the terms and conditions of those Awards. For awards
granted on or after October 1, 2020 pursuant to the Long-Term Incentive Program (LTIP) and/or
Performance Stock Program (PSP), awards will be prorated based on the number of days worked in
the 12 months following the October 1 grant date, with a minimum of 28 days worked beyond October
1.
This Separation Letter & Release does not alter the rights and obligations that you may have under the
Procter & Gamble 2019 Stock & Incentive Compensation Plan, the Procter & Gamble 2014 Stock &
Incentive Compensation Plan, the Procter & Gamble 2009 Stock and Incentive Compensation Plan,
the Procter & Gamble 2001 Stock and Incentive Plan, the Procter & Gamble 1992 Stock Plan, and the
Gillette Company 2004 Long-Term Incentive Plan.
-- 37 of 53 --
Release of Claims - Including
Employment Claims: You hereby release P&G from any and all claims or rights you may have against P&G. The term
“P&G” includes The Procter & Gamble Company and any of its present, former and future owners,
parents, affiliates and subsidiaries, and its and their directors, officers, shareholders, employees,
agents, benefit plans, trustees, fiduciaries, servants, representatives, predecessors, successors and
assigns. This release applies to claims about which you now know or may later discover, and includes
but is not limited to: (1) claims arising under the Age Discrimination in Employment Act ("ADEA"),
29 U.S.C. § 621, et seq.; (2) claims arising under any other federal, state or local law, regulation or
ordinance or other order that regulates the employment relationship and/or employee benefits; and (3)
claims arising out of or relating in any way to your employment with P&G or the conclusion of that
employment. This release does not apply to claims that may arise after the date you sign this letter or
that may not be released under applicable law.
Governmental Agencies: Nothing in this Separation Letter & Release prohibits or prevents you from
filing a charge with or participating, testifying, or assisting in any investigation, hearing, or other
proceeding before the U.S. Equal Employment Opportunity Commission, the National Labor
Relations Board or a similar agency enforcing federal, state or local anti-discrimination laws.
However, to the maximum extent permitted by law, you agree that if such an administrative claim is
made to such an anti-discrimination agency, you shall not be entitled to recover any individual
monetary relief or other individual remedies. Nothing in this Separation Letter & Release prohibits
you from: (1) reporting possible violations of federal law or regulations, including any possible
securities laws violations, to any governmental agency or entity, including but not limited to the U.S.
Department of Justice, the U.S. Securities and Exchange Commission, the U.S. Congress, or any
agency Inspector General; (2) making any other disclosures that are protected under the
whistleblower provisions of federal law or regulations; or (3) otherwise fully participating in any
federal whistleblower programs, including but not limited to any such programs managed by the U.S.
Securities and Exchange Commission and/or the Occupational Safety and Health Administration.
You understand you do not need the prior authorization from the Company to make any such reports
or disclosures, and you are not required to notify the Company that you have made such reports or
disclosures. Moreover, nothing in this Separation Letter & Release prohibits or prevents you from
receiving individual monetary awards or other individual relief by virtue of participating in such
federal whistleblower programs.
Return of P&G Property: You agree that by your Employment Separation Date, you will return to P&G in good condition all of
its equipment, materials and information that were in your possession, custody or control (including,
but not limited to, computers, phones, iPads, tablets files, documents, credit cards, keys and
identification badges). You further agree that you will provide your manager with all passwords to
P&G electronic communication and data systems before your Employment Separation Date.
Confidential Business
Information:
Consistent with the “Information for the Departing Employee” document reviewed with you prior to
your Employment Separation Date, you agree to protect P&G business information. Subject to the
“Government Agencies” paragraph in the above Release of Claims, you agree not to disclose or
transfer to yourself or others any P&G business information, even information you may have created
yourself or to which you may have contributed as a P&G employee. Please refer to the “Information
for the Departing Employee” document for more information.
-- 38 of 53 --
Continuing Cooperation (this
paragraph should be used for
R&D employees)
Regardless of whether you sign this Agreement and in the event it becomes necessary, following your
Employment Separation Date, you are required to cooperate in executing any and all papers required
for filing and prosecuting any patent applications and establishing P&G’s ownership of all inventions
relating to its business which are made by employees hired to invent or create. You understand that
you will not receive any additional compensation for such cooperation.
No Other Agreements: Except as specifically set forth in this Paragraph (“No Other Agreements”), this letter supersedes any
prior written or oral agreements between P&G and you concerning the termination of your
employment and any benefits you might receive following that event. This letter is neither a
Negotiated Separation Agreement under the Procter & Gamble Basic Separation Program nor an
agreement under any other separation program or plan sponsored by The Procter & Gamble Company
or any of its subsidiaries. This letter does not alter your rights and obligations under the terms of the
P&G Profit Sharing and Employee Stock Ownership Plan, other retirement plans, the P&G Stock and
Incentive Compensation Plan, and other compensation plans.
To accept the terms set forth in this letter, please sign below. By signing below, you acknowledge that you have read the entire letter,
that you understand it, and that you voluntarily accept its terms. You further agree that you understand this is a legally binding
agreement, that you have been advised to consult with an attorney, that you have been given 21 days to consider this Separation
Letter & Release and that you can revoke your acceptance within seven days of your acceptance by providing written notification to
your human resources manager. Finally, you understand that (1) this Separation Letter & Release includes the release of all claims
and (2) you are waiving unknown claims and are doing so intentionally and voluntarily.
Sincerely,
The Procter & Gamble Company
By: ________________________
Accepted and agreed to this _______ day of ___________, 20__.
_________________________________
[INSERT EMPLOYEE NAME]
-- 39 of 53 --
EXHIBIT (10-2)
Company’s Form of Separation Agreement & Release
-- 40 of 53 --
SEPARATION AGREEMENT AND RELEASE
To: «Employee_Name»
Date: «Actual_Offer_Date»
«Company» (“P&G”) is willing to provide you with certain assistance in connection with your employment separation from the
Company. The following describes the terms under which you are separating from employment. Your receipt of the benefits
described below is conditioned upon your accepting and abiding by the terms of this Agreement.
Last Day of Employment: Your last day of employment will be «Exit_Date», referred to as your “Last Day of Employment.”
You understand and agree that if P&G determines that you engaged in misconduct during your
employment, or if you fail to perform your work and responsibilities in a satisfactory manner up to
and including your Last Day of Employment, P&G may terminate your employment immediately
and will not provide, nor be obligated to provide, the payment(s) and other benefits described in this
Agreement. Otherwise, unless noted below, your pay and benefits will cease as of your Last Day of
Employment.
Separation Payment: As soon as administratively practical after your Last Day of Employment, P&G will provide you
with a Separation Payment of «Total_Amount», less legally required withholdings and deductions.
In no event will payment be made before expiration of the seven-day revocation period discussed
below or later than the March 15th of the year following the year which includes your last day of
employment.
Amounts you owe to P&G as of your Last Day of Employment, including, but not limited to, wage
and/or benefit overpayments and unpaid loans, will also be deducted from the Separation Payment.
Payment for Unvested PST: If you are not fully-vested in the Procter & Gamble Profit Sharing Trust and Employee Stock
Ownership Plan (“PST”) as of your Last Day of Employment, as soon as administratively practical
after your Last Day of Employment, but no later than the March 15th of the year following the year
which includes your Last Day of Employment, you will receive a lump sum payment in an amount
substantially equivalent to the non-vested credits in your account in the PST.
STAR Awards: As of your Last Day of Employment, if you worked at least 28 days (4 calendar weeks) during that
fiscal year, you will receive a pro-rated STAR award for that fiscal year. Your STAR award will be
pro-rated by dividing the number of calendar days during the fiscal year from July 1 through your
Last Day of Employment by 365. Your STAR award will be paid in cash in the September (but no
later than September 15th) immediately following the end of the fiscal year in which you terminate.
-- 41 of 53 --
Equity Awards Your separation will be treated as a Special Separation for purposes of any outstanding equity awards
granted under the Procter & Gamble 2009 Stock and Incentive Compensation Plan, the Procter &
Gamble 2001 Stock and Incentive Compensation Plan, the Procter & Gamble 1992 Stock Plan, or the
Gillette Company 2004 Long-Term Incentive Plan and, as a result, you will retain the awards subject to
the original terms and conditions of the awards. You will also retain awards granted under the Procter &
Gamble 2014 Stock and Incentive Compensation Plan and the Procter & Gamble 2019 Stock and
Incentive Compensation Plan subject to the terms and conditions of those Awards. For awards granted
on or after October 1, 2020, pursuant to the Long-Term Incentive Program (LTIP) and/or Performance
Stock Program (PSP), awards will be prorated based on the number of days worked in the 12 months
following the October 1 grant date, with a minimum requirement of 28 days worked beyond October 1.
This agreement does not alter the rights and obligations that you may have under the Procter & Gamble
2019 Stock and Incentive Compensation Plan, the Procter & Gamble 2014 Stock and Incentive
Compensation Plan, the Procter & Gamble 2009 Stock and Incentive Compensation Plan, the Procter &
Gamble 2001 Stock and Incentive Compensation Plan, the Procter & Gamble 1992 Stock Plan, and the
Gillette Company 2004 Long-Term Incentive Plan.
Current Medical, Dental,
and Life Insurance
Benefits:
If you are enrolled in P&G’s active health (including medical, prescription drug, and EAP coverage),
active dental, and company-paid life insurance coverage, that coverage will continue under the same
terms until «Benefits_End_Date».
If you continue to receive P&G active health coverage during the extension of benefits period, that
coverage will be impacted if you (or your eligible dependents, including but not limited to your spouse
or domestic partner) are or become eligible for Medicare. For more information on this impact, see the
Coordination With Medicare section in the Summary Plan Description for your P&G active health
coverage.
If you continue to receive P&G active health coverage during the extension of benefits period, you may
be entitled to continue your health and dental coverage under COBRA when the extension of benefits
period ends. If you are entitled to COBRA continuation coverage, you will receive a notice of your right
to elect COBRA.
Any life insurance coverage other than company-paid life insurance coverage will not continue during
this time.
-- 42 of 53 --
Retiree Medical and Dental
Benefits:
If you were eligible for P&G retiree healthcare coverage on your Last Day of Employment, you will
be eligible to enroll in P&G’s retiree medical and dental insurance coverage. You are eligible for
P&G retiree healthcare coverage if you satisfy the regular retiree eligibility rules (i.e., you are a
Regular Retiree) as of your Last Day of Employment. Under the terms of this Agreement, you also
are eligible for P&G retiree healthcare coverage as a Special Retiree by satisfying the Rule of 70 as
of your Last Day of Employment. You satisfy the Rule of 70 when your full years of age plus your
full years of service equal 70 . If you are eligible for P&G’s retiree healthcare coverage as either a
Regular Retiree or a Special Retiree as of your Last Day of Employment, you should contact P&G
Employee Care before your extension of coverage ends to request retiree healthcare enrollment
information. For details regarding the terms and conditions of your retiree health coverage, please
refer to and review the summary plan descriptions, available at PGOne → Life and Career
Important Note: If you become employed by a direct competitor of P&G (as determined by P&G’s
Chief Human Resources Officer) in any capacity, you will not be eligible for coverage under P&G’s
retiree healthcare coverage as long as you remain employed by such competitor. If you have
questions, please contact the P&G Employee Care at [phone #].
Outplacement Services: P&G’s outplacement supplier, Right Management Consultants, will provide services to assist you in
managing your transition to a new future, based on your interest. Services include pre-decision
counseling, career transition programs, and job development opportunities. Right Management
Consultants will also assist you in preparing for your job search, including résumé preparation, cover
letters, other written materials and interview and networking training.
After you accept this Agreement, you may begin utilizing outplacement services on a limited basis
prior to your Last Day of Employment, consistent with the needs of the business and your
responsibilities to complete and/or transition your work. Note that you must begin utilizing
outplacement services within 45 days of your Last Day of Employment to be eligible for this benefit.
_______________
Special rules apply to Gillette Heritage Employees with regard to retiree medical eligibility and the retiree medical cost sharing
under the retiree medical plan. If you are a Gillette Heritage Employee, you will receive a separate handout on your retiree medical
eligibility.
1
1
-- 43 of 53 --
No Consideration Without
Executing this Agreement:
You affirm that you understand and agree that you would not receive the separation payment and/or
benefits specified in this Agreement without executing this Agreement and fulfilling the promises
contained in it. Except as provided in this Agreement or under the terms and conditions of an
applicable benefit plan or policy sponsored by P&G, you shall not be due any payments or benefits
from P&G in connection with the termination of your employment.
Continued Employment
Through Your Last Day of
Employment:
You agree to perform your work and responsibilities as an employee in a satisfactory manner up to
and including your Last Day of Employment, including compliance with all provisions of this
“Separation Agreement and Release.” If P&G determines that you have engaged in serious
misconduct during your employment, you understand and agree that P&G may terminate your
employment immediately and will not provide, nor will it be obligated to provide, you with the
Separation Payment, medical benefits, outplacement and other benefits described above. If you have
already received any such pay or benefits, you agree to repay them to P&G upon demand.
Nonadmission of Wrongdoing: You affirm that you understand and agree that neither this Agreement nor the furnishing of the
consideration for this Agreement, including the Separation Payment, shall be deemed or construed
at any time for any purpose as an admission by P&G of wrongdoing or evidence of any liability or
unlawful conduct of any kind.
Release of Claims – Including
Age Discrimination and
Employment Claims:
In consideration of the Separation Payment and other benefits provided above to which you would
not have been entitled under any existing P&G Policy, you release P&G from any and all claims
you have against P&G. The term “P&G” includes «Company» and any of its present, former and
future owners, parents, affiliates and subsidiaries, and its and their directors, officers, shareholders,
employees, agents, servants, representatives, predecessors, successors and assigns and their
employee benefit plans and programs and their administrators and fiduciaries.
This release applies to claims about which you now know or may later discover, and includes but is
not limited to: (1) claims arising under the Age Discrimination in Employment Act, 29 U.S.C. §
621, et seq.; (2) claims arising out of or relating in any way to your employment with P&G or the
conclusion of that employment; (3) claims arising under any federal, state and local employment
discrimination laws, regulations or ordinances or other orders that relate to the employment
relationship and/or employee benefits; and (4) any other federal, state or local law, rule, regulation
or ordinance, public policy, contract, tort or common law.
This release does not apply to claims that may arise after the date you accept this Agreement or that
may not be released under applicable law.
You are not waiving any rights you may have to: (a) your own vested accrued employee benefits
under the P&G health, welfare, or retirement benefit plans as of the Last Day of Employment; (b)
benefits and/or the right to seek benefits under applicable workers’ compensation and/or
unemployment compensation statutes; (c) pursue claims which by law cannot be waived by signing
this Agreement; (d) enforce this Agreement; and/or (e) challenge the validity of this Agreement.
You agree that the decision as to what would be your Last Day of Employment was made prior to
your accepting and executing this Agreement, and you agree that you are releasing any claim in
connection with the separation of your employment.
If any claim is not subject to release, to the extent permitted by law, you agree that you waive any
right or ability to be a class or collective action representative or to otherwise participate in any
putative or certified class, collective or multi-party action or proceeding based on such a claim in
which P&G is a party.
-- 44 of 53 --
Governmental Agencies: Nothing in this Separation Letter & Release prohibits or prevents you from
filing a charge with or participating, testifying, or assisting in any investigation, hearing, or other
proceeding before the U.S. Equal Employment Opportunity Commission, the National Labor
Relations Board or a similar agency enforcing federal, state or local anti-discrimination laws.
However, to the maximum extent permitted by law, you agree that if such an administrative claim is
made to such an anti-discrimination agency, you shall not be entitled to recover any individual
monetary relief or other individual remedies. Nothing in this Separation Letter & Release, including
but not limited to the “Release of Claims – Including Age Discrimination and Employment Claims”
and the “Confidential, Proprietary, Trade Secret Information & Period of Non-Competition” sections
of this Separation Letter & Release, prohibits you from: (1) reporting possible violations of federal
law or regulations, including any possible securities laws violations, to any governmental agency or
entity, including but not limited to the U.S. Department of Justice, the U.S. Securities and Exchange
Commission, the U.S. Congress, or any agency Inspector General; (2) making any other disclosures
that are protected under the whistleblower provisions of federal law or regulations; or (3) otherwise
fully participating in any federal whistleblower programs, including but not limited to any such
programs managed by the U.S. Securities and Exchange Commission and/or the Occupational Safety
and Health Administration. You understand you do not need the prior authorization from the
Company to make any such reports or disclosures, and you are not required to notify the Company
that you have made such reports or disclosures. Moreover, nothing in this Separation Letter &
Release prohibits or prevents you from receiving individual monetary awards or other individual
relief by virtue of participating in such federal whistleblower programs.
Confidential, Proprietary,
Trade Secret Information &
Period of Non-Competition:
Subject to the “Governmental Agencies” portion of the “Release of Claims – Including Age
Discrimination and Employment Claims” above, you agree that you will not use or share any
confidential, proprietary or trade secret information about any aspect of P&G’s business with any
non-P&G employee or business entity at any time in the future. You further agree that you will not
obtain, transfer or have in your possession any confidential, proprietary or trade secret information
on or after your last day of employment, even information you may have created yourself or to which
you may have contributed as a P&G employee. Confidential, proprietary or trade secret information
includes, but is not limited to, marketing and advertising plans, pricing information, upstream plans,
specific areas of research and development, project work, product formulation, processing methods,
assignments of individual employees, testing and evaluation procedures, cost figures, construction
plans, and special techniques or methods of any kind.
Notwithstanding the requirements of confidentiality contained in this section, the federal Defend
Trade Secrets Act of 2016 immunizes you against criminal and civil liability under federal or state
trade secret laws for your disclosure of trade secrets that is made i) in confidence to a federal, state,
or local government official, either directly or indirectly, or to an attorney solely for the purpose of
reporting or investigating a suspected violation of law; ii) in a complaint or other document filed in a
lawsuit or other proceeding, if such filing is made under seal; or iii) to your attorney for use in a
lawsuit alleging retaliation for reporting a suspected violation of law, provided that any document
containing the trade secret is filed under seal and you do not otherwise disclose the trade secret,
except pursuant to court order.
-- 45 of 53 --
You further understand and agree that, unless you have prior written consent from P&G, you will not engage
in any activity or provide any services for a period of three (3) years following your Last Day of
Employment in connection with the manufacture, development, advertising, promotion or sale of any
product which is the same as, similar to, or competitive with any products of P&G or its subsidiaries
(including both existing products as well as products in development which are known to you, as a
consequence of your employment with P&G):
1. With respect to which your work has been directly concerned at any time during the two (2) years
preceding your Last Day of Employment; or
2. With respect to which during that period of time you, as a consequence of your job performance and
duties, acquired knowledge of trade secrets or other confidential information of P&G.
For the purposes of this section, it shall be conclusively presumed that you have knowledge or information
to which you were directly exposed through the actual receipt of memos or documents containing such
information or through actual attendance at meetings at which such information was discussed or disclosed.
The provisions of this section are not in lieu of, but are in addition to, your continuing obligation to not use
or disclose P&G’s trade secrets and confidential information known to you until any particular trade secret
or confidential information becomes generally known (through no fault of yours). Information regarding
products in development, in test market or being marketed or promoted in a discrete geographic region,
which information P&G is considering for a broader use, shall not be deemed generally known until such
broader use is actually commercially implemented. Also, “generally known” means known throughout the
domestic United States industry or, if you have job responsibilities outside of the United States, the
appropriate foreign country or countries’ industry.
If any restriction in this section is found by any court of competent jurisdiction or arbitrator to be
unenforceable because it extends for too long a period of time or over too great a range of activities or in too
broad a geographic area, it will be modified and interpreted to extend only over the maximum period of
time, range of activities or geographic area so that it may be enforceable.
As a participant in the 2009 Stock and Incentive Compensation Plan, the 2001 Stock and Incentive
Compensation Plan, or the 1992 Stock Plan, you are also bound by the terms of Article F – Restrictions &
Covenants of those plans, which are incorporated herein by reference.
If you are a participant in the Procter & Gamble 2019 Stock and Incentive Compensation Plan and the
Procter & Gamble 2014 Stock and Incentive Compensation Plan, you are also bound by the terms of Article
6 – Restrictions and Covenants of this plan which are incorporated herein by reference.
-- 46 of 53 --
Non-Solicitation You acknowledge, as a participant in the Procter & Gamble 2019 Stock and Incentive
Compensation Plan, the Procter & Gamble 2014 Stock & Incentive Compensation Plan, the
Procter & Gamble 2009 Stock and Incentive Compensation Plan, the Procter & Gamble 2001
Stock and Incentive Plan, the Procter & Gamble 1992 Stock Plan, and/or the Gillette Company
2004 Long-Term Incentive Plan that you are bound to comply with the Plans’ non-solicitation
obligations. Specifically, you agree that you will not, at any time following your Employment
Separation Date, attempt to directly or indirectly induce any employee of P&G or its affiliates or
subsidiaries to be employed or perform services elsewhere or attempt directly or indirectly to
solicit the trade or business of any current or prospective customer, supplier or partner of P&G or
its affiliates or subsidiaries.
Acknowledgements and
Affirmations: Subject to the “Governmental Agencies” portion of the “Release of Claims – Including Age
Discrimination and Employment Claims” above, you affirm that you have not filed, caused to be
filed, or presently are a party to any claim against P&G.
You affirm that you have been paid and/or have received all compensation, wages, bonuses,
commissions, and/or benefits which are due and payable as of the date you sign this Agreement.
To the extent that you are required to report hours worked, you affirm that you have reported all
hours worked as of the date you sign this Agreement.
You affirm that you have been granted any leave to which you were entitled under the Family and
Medical Leave Act or related state or local leave or disability accommodation laws.
You further affirm that you have no known workplace injuries or occupational diseases that have
not been reported.
Assignment of Intellectual
Property:
You will promptly and fully disclose, transfer and assign to P&G all inventions and any other
intellectual property (collectively “Intellectual Property”) made or conceived by you during your
employment with P&G. You agree to fully cooperate in executing any papers required for
establishing or protecting the Intellectual Property and for establishing P&G’s ownership, even if
such cooperation is necessary after your Last Day of Employment.
-- 47 of 53 --
Return of P&G Property: You agree that on or before your Last Day of Employment, you will return to P&G in good condition
all of its equipment, materials and information that were in your possession, custody or control
(including, but not limited to, computers, files, documents, credit cards, keys and identification
badges). You further agree that you will provide your manager with all passwords to P&G electronic
communication and data systems before your Last Day of Employment. You further agree that on or
before your Last Day of Employment, you will return or if directed to do so by your immediate
manager, delete (i.e., destroy all copies of) any and all P&G confidential, proprietary or trade secret
information you have maintained in your possession, custody, or control in paper, electronic and/or
digital formats, including but not limited to, any such confidential, proprietary, or trade secret
information (e.g., files, documents, etc.) that you may have electronically or digitally processed or
stored on P&G-issued or on personally-owned or maintained digital devices and/or service accounts.
Such digital devices and/or service accounts may include, but are not limited to desktop and laptop
computers, notebooks, tablets, iPads, mobile phones, smartphones, personal digital assistants
(PDAs), USB and flash drives, external hard drives, CDs, DVDs, and/or external file processing or
storage provided by cloud service providers such as box.net, dropbox, Google docs, etc.
Ethics Compliance: Subject to the “Governmental Agencies” portion of the “Release of Claims – Including Age
Discrimination and Employment Claims” above, you agree that you provided P&G all information
known to you regarding any violations of the Procter & Gamble Worldwide Business Conduct
Manual and/or any other violations of P&G policy or the law.
Agreement to Arbitrate
Disputes:
Resolving any future differences we may have in the courts can take a long time and be expensive.
You and P&G therefore agree that the only remedy for all disputes that are not released by this
Agreement or that arise out of your employment with or separation from P&G, or any aspect of this
Agreement, will be to submit any such disputes (with the exception noted at the end of this section)
to final and binding arbitration in accordance with the National Rules for Resolution of Employment
Disputes of the American Arbitration Association then in effect.
You and P&G agree that the aggrieved party must send written notice of any claim to the other party
by certified mail, return receipt requested. Written notice for P&G will be sent to: Secretary, One
Procter & Gamble Plaza, Cincinnati, OH 45202, and to you at the most current address shown for
you in P&G’s records. The arbitrator will apply Ohio law. At your written request, P&G will
reimburse you for all fees and costs charged by the American Arbitration Association and its
arbitrator to the extent they exceed the applicable fees and costs that would have been charged by a
court of competent jurisdiction had your claim been filed in court.
There is one exception to this section. P&G may seek injunctive relief in any court of competent
jurisdiction if it has reason to believe that you have violated or are about to violate (1) the terms of
the “Confidential, Proprietary, Trade Secret Information & Period of Non-Competition” section
above, or (2) if you are a participant in the 2009 Stock and Incentive Compensation Plan, the 2001
Stock and Incentive Compensation Plan, or the 1992 Stock Plan, the terms of Article F – Restrictions
& Covenants of those plans or (3) if you are a participant in the 2014 Stock and Incentive
Compensation Plan, the terms of Article 6 – Restrictions & Covenants of those plans.
-- 48 of 53 --
Severability: If any court of competent jurisdiction or arbitrator should later find that any portion of this
Agreement is invalid, that invalidity will not affect the enforceability of any other portion of this
Agreement.
Employment References: You understand that P&G’s historical policy is to not provide employment references to prospective
employers. However, P&G is willing to waive that policy in your case on the following basis: You
authorize your manager or human resources representative to provide an employment reference upon
written or verbal request. In return, you release any claim against P&G and will not bring a lawsuit in
court against P&G based upon that employment reference (or lack thereof). You agree that you will
refer all reference inquiries to your manager or human resources representative only. You further
understand that all disputes regarding employment references or the lack thereof must be resolved
through the arbitration process described above.
No Reliance: This Agreement sets forth the entire agreement between you and P&G and fully supersedes any prior
agreements or understanding between the parties except that if you are a participant in the 2009
Stock and Incentive Compensation Plan, the 2001 Stock and Incentive Compensation Plan, or the
1992 Stock Plan, the terms of Article F – Restrictions & Covenants of those plans remain in full
force and effect and are incorporated herein by reference and if you are a participant in the Procter &
Gamble 2019 Stock and Incentive Compensation Plan or the Procter & Gamble 2014 Stock and
Incentive Compensation Plan, the terms of Article 6 – Restrictions & Covenants of those plans
remain in full force and are in effect and are incorporated herein by reference. In deciding to accept
this Agreement, you agree that you have not relied upon any statements or promises by P&G, its
managers, agents or employees, other than those set forth in this Agreement. No other promises or
agreements concerning the matters described in this Agreement shall be binding unless in a
subsequent document signed by these parties.
Your Attorney: You acknowledge that you have been and hereby are advised to consult with legal counsel before
accepting this Agreement and have either done so or have voluntarily declined to do so.
Timing for Acceptance or
Revocation:
You have forty-five (45) calendar days in which to consider this Agreement in which you waive
important rights, including those under the Age Discrimination in Employment Act of 1967. If you
choose to sign this Agreement, please do so by indicating your acceptance of this Agreement with
your electronic signature in P&G’s electronic system. We advise you to consult with an attorney of
your choosing prior to signing this Agreement. Further, you may within seven (7) calendar days
following the date you sign this Agreement, cancel and terminate it by giving written notice of your
intention to revoke the Agreement to your immediate manager, and by returning to P&G any
remuneration or benefits that have been advanced to you in anticipation of your not revoking your
agreement and to which you are not entitled. If notice of your revocation is mailed, it must be
postmarked within seven (7) calendar days after you sign this Agreement.
You agree that any modifications, material or otherwise, made to this Agreement, do not restart or
affect in any manner the original up to forty-five (45) calendar day consideration period.
The benefits described in this Agreement and pursuant to the summary plan description for the Procter & Gamble Basic Separation
Program for U.S. Employees, are the special benefits you will receive by signing this Agreement. To the extent this Agreement
describes benefits under other benefit plans and policies sponsored by P&G, these special benefits are also described in the summary
plan descriptions for those plans. As such, nothing in this Agreement amends or changes the terms of any P&G-sponsored employee
benefit plan or policy.
After your Last Day of Employment, you will no longer be an active P&G employee, which may affect your coverage under those
plans and policies. For example, plans may require that you enroll in Medicare to be eligible for coverage. For more information on
how not being an active P&G employee may affect your coverage, please refer to and review the summary plan descriptions for each
plan, available at PGOne → Life and Career.
-- 49 of 53 --
EXHIBIT 31.1
Rule 13a-14(a)/15d-14(a) Certifications
I, David S. Taylor, certify that:
(1) I have reviewed this quarterly report on Form 10-Q of The Procter & Gamble Company;
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
(5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
/s/ DAVID S. TAYLOR
(David S. Taylor)
Chairman of the Board, President and Chief Executive Officer
April 20, 2021
Date
-- 50 of 53 --
EXHIBIT 31.2
Rule 13a-14(a)/15d-14(a) Certifications
I, Andre Schulten, certify that:
(1) I have reviewed this quarterly report on Form 10-Q of The Procter & Gamble Company;
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
(5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
/s/ ANDRE SCHULTEN
(Andre Schulten)
Chief Financial Officer
April 20, 2021
Date
-- 51 of 53 --
EXHIBIT 32.1
Section 1350 Certifications
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter & Gamble
Company (the “Company”) certifies to his knowledge that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2021 fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in that Form 10-Q fairly presents, in all material respects, the financial conditions and results of operations of the Company.
/s/ DAVID S. TAYLOR
(David S. Taylor)
Chairman of the Board, President and Chief Executive Officer
April 20, 2021
Date
A signed original of this written statement required by Section 906 has been provided to The Procter & Gamble Company and will be retained by The Procter &
Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.
-- 52 of 53 --
EXHIBIT 32.2
Section 1350 Certifications
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter & Gamble
Company (the “Company”) certifies to his knowledge that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2021 fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in that Form 10-Q fairly presents, in all material respects, the financial conditions and results of operations of the Company.
/s/ ANDRE SCHULTEN
(Andre Schulten)
Chief Financial Officer
April 20, 2021
Date
A signed original of this written statement required by Section 906 has been provided to The Procter & Gamble Company and will be retained by The Procter &
Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.
-- 53 of 53 --